

CORRECTED VERSION

(19) World Intellectual Property Organization
International Bureau



(43) International Publication Date
6 July 2000 (06.07.2000)

PCT

(10) International Publication Number
WO 00/38716 A1

(51) International Patent Classification⁷: A61K 41/00,
A61P 35/00

(21) International Application Number: PCT/US99/30669

(22) International Filing Date:
22 December 1999 (22.12.1999)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
60/113,786 23 December 1998 (23.12.1998) US
09/385,214 27 August 1999 (27.08.1999) US

(71) Applicant (for all designated States except US): G.D. SEARLE & CO. [US/US]; Corporate Patent Dept., P.O. Box 5110, Chicago, IL 60680-5110 (US).

(72) Inventors; and

(75) Inventors/Applicants (for US only): MCKEARN, John, P. [US/US]; 18612 Babler Meadows Drive, St. Louis, MO 63038 (US). MASFERRER, Jaime, L. [CL/US]; 1213 Blairshire, Ballwin, MO 63011 (US). MILAS, Luka [US/US]; 2708 Quenby, Houston, TX 77005 (US).

(74) Agents: WILLIAMS, Roger, A. et al.; G.D. Searle & Co., Corporate Patent Dept., P.O. Box 5110, Chicago, IL 60680-5110 (US).

(81) Designated States (national): AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW.

(84) Designated States (regional): ARIPO patent (GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).

Published:
— With international search report.

(48) Date of publication of this corrected version:
30 November 2000

(15) Information about Correction:
see PCT Gazette No. 48/2000 of 30 November 2000, Section II

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(54) Title: COMBINATION THERAPY OF RADIATION AND A COX-2 INHIBITOR FOR THE TREATMENT OF NEOPLASIA

(57) Abstract: The present invention provides methods to treat or prevent neoplasia disorders in a mammal using a combination of radiation therapy and a cyclooxygenase-2 inhibitor.

WO 00/38716 A1

-1-

**COMBINATION THERAPY OF RADIATION AND A COX-2 INHIBITOR
FOR THE TREATMENT OF NEOPLASIA**

Related Case

5 This application is a continuation-in-part of
United States patent application Serial No. 60/113,786,
filed December 23, 1998 and 09/385,214 filed August 27,
1999.

10 Field of the Invention

 The present invention relates to a combination of
radiation therapy and a cyclooxygenase-2 (COX-2)
inhibitor for treatment of neoplasia disorders. More
specifically, this invention relates to the use of COX-
15 2 inhibitors in combination with radiation therapy for
treating cancer.

Background of the Invention

 A neoplasm, or tumor, is an abnormal, unregulated,
20 and disorganized proliferation of cell growth. A
neoplasm is malignant, or cancerous, if it has
properties of destructive growth, invasiveness and
metastasis. Invasiveness refers to the local spread of
a neoplasm by infiltration or destruction of
25 surrounding tissue, typically breaking through the
basal laminae that define the boundaries of the
tissues, thereby often entering the body's circulatory
system. Metastasis typically refers to the
dissemination of tumor cells by lymphatics or blood
30 vessels. Metastasis also refers to the migration of
tumor cells by direct extension through serous
cavities, or subarachnoid or other spaces. Through

-2-

the process of metastasis, tumor cell migration to other areas of the body establishes neoplasms in areas away from the site of initial appearance.

Cancer is now the second leading cause of death in
5 the United States and over 8,000,000 persons in the United States have been diagnosed with cancer. In 1995, cancer accounted for 23.3% of all deaths in the United States.

Cancer is not fully understood on the molecular
10 level. It is known that exposure of a cell to a carcinogen such as certain viruses, certain chemicals, or radiation, leads to DNA alteration that inactivates a "suppressive" gene or activates an "oncogene".
Suppressive genes are growth regulatory genes, which
15 upon mutation, can no longer control cell growth.
Oncogenes are initially normal genes (called prooncogenes) that by mutation or altered context of expression become transforming genes. The products of transforming genes cause inappropriate cell growth.
20 More than twenty different normal cellular genes can become oncogenes by genetic alteration. Transformed cells differ from normal cells in many ways, including cell morphology, cell-to-cell interactions, membrane content, cytoskeletal structure, protein secretion,
25 gene expression and mortality.

Cancer is now primarily treated with one or a combination of three types of therapies: surgery, radiation, and chemotherapy. Surgery involves the bulk removal of diseased tissue. While surgery is sometimes
30 effective in removing tumors located at certain sites, for example, in the breast, colon, and skin, it cannot

-3-

be used in the treatment of tumors located in other areas, inaccessible to surgeons, nor in the treatment of disseminated neoplastic conditions such as leukemia.

Chemotherapy involves the disruption of cell replication or cell metabolism. It is used most often in the treatment of breast, lung, and testicular cancer.

The adverse effects of systemic chemotherapy used in the treatment of neoplastic disease is most feared by patients undergoing treatment for cancer. Of these adverse effects nausea and vomiting are the most common and severe side effects. Other adverse side effects include cytopenia, infection, cachexia, mucositis in patients receiving high doses of chemotherapy with bone marrow rescue or radiation therapy; alopecia (hair loss); cutaneous complications such as pruritus, urticaria, and angioedema; neurological complications; pulmonary and cardiac complications in patients receiving radiation or chemotherapy; and reproductive and endocrine complications (M. Abeloff, et al., Alopecia and Cutaneous Complications, in Clinical Oncology 755-56 (Abeloff, ed. 1992)).

Chemotherapy-induced side effects significantly impact the quality of life of the patient and may dramatically influence patient compliance with treatment.

Additionally, adverse side effects associated with chemotherapeutic agents are generally the major dose-limiting toxicity (DLT) in the administration of these drugs. For example, mucositis, is one of the major dose limiting toxicity for several

-4-

anticancer agents, including the antimetabolite
cytotoxic agents 5-FU, methotrexate, and antitumor
antibiotics, such as doxorubicin. Many of these
chemotherapy-induced side effects if severe, may
5 lead to hospitalization, or require treatment with
analgesics for the treatment of pain.

In general, radiation therapy is employed as
potentially curative therapy for patients who present
with clinically localized disease and are expected to
10 live at least 10 years.

For example, approximately 70% of newly
diagnosed prostate cancer patients fall into this
category. Approximately 10% of these patients (7% of
total patients) undergo radiation therapy.
15 Approximately 80% of patients who have undergone
radiation as their primary therapy have disease
persistence or develop recurrence or metastasis
within five years after treatment. Currently, most
of these radiotherapy patients generally do not
20 receive any immediate follow-up therapy. Rather,
they are monitored frequently, such as for elevated
Prostate Specific Antigen ("PSA"), which is the
primary indicator of recurrence or metastasis in
prostate cancer.

25 The adverse side effects induced by
chemotherapeutic agents and radiation therapy have
become of major importance to the clinical management
of cancer patients.

Colorectal Cancer

30 Survival from colorectal cancer depends on the
stage and grade of the tumor, for example precursor

-5-

adenomas to metastatic adenocarcinoma. Generally, colorectal cancer can be treated by surgically removing the tumor, but overall survival rates remain between 45 and 60 percent. Colonic excision
5 morbidity rates are fairly low and is generally associated with the anastomosis and not the extent of the removal of the tumor and local tissue. In patients with a high risk of reoccurrence, however, chemotherapy has been incorporated into the
10 treatment regimen in order to improve survival rates.

Tumor metastasis prior to surgery is generally believed to be the cause of surgical intervention failure and up to one year of chemotherapy is required
15 to kill the non-excised tumor cells. As severe toxicity is associated with the chemotherapeutic agents, only patients at high risk of recurrence are placed on chemotherapy following surgery.

Prostate Cancer

20 Prostate cancer is now the leading form of cancer among men and the second most frequent cause of death from cancer in men. It is estimated that more than 165,000 new cases of prostate cancer were diagnosed in 1993, and more than 35,000 men died from
25 prostate cancer in that year. Additionally, the incidence of prostate cancer has increased by 50% since 1981, and mortality from this disease has continued to increase. Previously, most men died of other illnesses or diseases before dying from their
30 prostate cancer. We now face increasing morbidity

-6-

from prostate cancer as men live longer and the disease has the opportunity to progress.

Current therapies for prostate cancer focus upon reducing levels of dihydrotestosterone to decrease or prevent growth of prostate cancer. Radiation alone or
5 in combination with surgery and/or chemotherapeutic agents is often used.

In addition to the use of digital rectal examination and transrectal ultrasonography, prostate-specific antigen (PSA) concentration is frequently used
10 in the diagnosis of prostate cancer.

U.S. Pat. No. 4,472,382 discloses treatment of benign prostatic hyperplasia (BPH) with an antiandrogen and certain peptides which act as LH-RH agonists. U.S. Pat. No. 4,596,797 discloses
15 aromatase inhibitors as a method of prophylaxis and/or treatment of prostatic hyperplasia. U.S. Pat. No. 4,760,053 describes a treatment of certain cancers which combines an LHRH agonist with an antiandrogen and/or an antiestrogen and/or at least
20 one inhibitor of sex steroid biosynthesis. U.S. Pat. No. 4,775,660 discloses a method of treating breast cancer with a combination therapy which may include surgical or chemical prevention of
25 ovarian secretions and administering an antiandrogen and an antiestrogen. U.S. Pat. No. 4,659,695 discloses a method of treatment of prostate cancer in susceptible male animals including humans whose testicular hormonal secretions are blocked by
30 surgical or chemical means, e.g. by use of an LHRH agonist, which comprises administering an

-7-

antiandrogen, e.g. flutamide, in association with at least one inhibitor of sex steroid biosynthesis, e.g. aminoglutethimide and/or ketoconazole.

Prostate Specific Antigen

5 One well known prostate cancer marker is Prostate Specific Antigen (PSA). PSA is a protein produced by prostate cells and is frequently present at elevated levels in the blood of men who have prostate cancer. PSA has been shown to correlate with tumor burden, 10 serve as an indicator of metastatic involvement, and provide a parameter for following the response to surgery, irradiation, and androgen replacement therapy in prostate cancer patients. It should be noted that Prostate Specific Antigen (PSA) is a completely 15 different protein from Prostate Specific Membrane Antigen (PSMA). The two proteins have different structures and functions and should not be confused because of their similar nomenclature.

Prostate Specific Membrane Antigen (PSMA)

20 In 1993, the molecular cloning of a prostate-specific membrane antigen (PSMA) was reported as a potential prostate carcinoma marker and hypothesized to serve as a target for imaging and cytotoxic treatment modalities for prostate cancer. 25 Antibodies against PSMA have been described and examined clinically for diagnosis and treatment of prostate cancer. In particular, Indium-111 labelled PSMA antibodies have been described and examined for diagnosis of prostate cancer and itrium-labelled 30 PSMA antibodies have been described and examined for the treatment of prostate cancer.

-8-

Pancreas Cancer

Approximately 2% of new cancer cases diagnoses in the United States is pancreatic cancer.

Pancreatic cancer is generally classified into two clinical types: 1) adenocarcinoma (metastatic and non-metastatic), and 2) cystic neoplasms (serous cystadenomas, mucinous cystic neoplasms, papillary cystic neoplasms, acinar cell systadenocarcinoma, cystic choriocarcinoma, cystic teratomas, and angiomatous neoplasms).

Ovary Cancer

Celomic epithelial carcinoma accounts for approximately 90% of ovarian cancer cases.

Preferred single agents that can be used in combination include: alkylating agents, ifosfamide, cisplatin, carboplatin, taxol, doxorubicin, 5-fluorouracil, methotrexate, mitomycin, hexamethylmelamine, progestins, antiestrogens, prednimustine, dihydroxybusulfan, galactitol, interferon alpha and interferon gamma.

Cancer of the fallopian tube is the least common type of ovarian cancer, accounting for approximately 400 new cancer cases per year in the United States. Papillary serous adenocarcinoma accounts for approximately 90% of all malignancies of the ovarian tube.

Prostaglandins are arachidonate metabolites produced in virtually all mammalian tissues and possess diverse biologic capabilities, including vasoconstriction, vasodilation, stimulation or inhibition of platelet aggregation, and

-9-

immunomodulation, primarily immunosuppression
(Moskowitz and Coughlins, *Stroke* 1981; 12: 882-86;
Leung and Mihich. *Nature* 1980; 597-600; Brunda et
al., *J. Immunol.* 1980; 124: 2682-7). They are
5 implicated in the promotion of development and
growth of malignant tumors (Honn et al.,
Prostaglandins 1981;21:833-64; Furuta et al.,
Cancer Res. 1989, 48, 3002-7; Taketo; *J. Natl.*
Cancer Inst. 1998, 90, 1609-20). They are also
10 involved in the response of tumor and normal tissues
to cytotoxic agents such as ionizing radiation
(Milas and Hanson, *Eur. J. Cancer* 1995, 31A, 1580-
5). Prostaglandin production is mediated by two
cyclooxygenase enzymes: COX-1 and COX-2.

15 Cyclooxygenase-1 (COX-1) is constitutively expressed
and is ubiquitous. Cyclooxygenase-2 (COX-2) is
induced by diverse inflammatory stimuli (Isakson et
al., *Adv. Pros. Throm. Leuk Res.* 1995, 23, 49-54).

Prostaglandin-mediated effects at both the
20 microenvironmental and cellular levels have been
implicated in the modulation of such response.
Prostaglandin E₂, and prostaglandin I₂ protect
jejunum crypt cells, and prostaglandin I₂ protects
B16 melanoma cells from radiation damage. Inhibition
25 of prostaglandin synthesis also induces an
accumulation of cells in the G₂+M phases of the cell
cycle, which are generally considered to be the most
sensitive to ionizing radiation. With the inhibition
of prostaglandin synthesis, prostaglandin-induced
30 immunosuppressive activity was diminished and
antitumor immunologic responses were able to

-10-

potentiate tumor response to radiation. Finally, prostaglandins are vasoactive agents and are thus likely to regulate tumor blood flow and perfusion.

Nonsteroidal anti-inflammatory drugs (NSAIDs) non-selectively inhibit both cyclooxygenase enzymes and consequently can prevent, inhibit, or abolish the effects of prostaglandins. Increasing evidence shows that NSAIDs can inhibit the development of cancer in both experimental animals and in humans, can reduce the size of established tumors, and can increase the efficacy of cytotoxic cancer chemotherapeutic agents. Our own investigations have demonstrated that indomethacin prolongs tumor growth delay and increases the tumor cure rate in mice after radiotherapy (Milas et al., *Cancer Res.* 1990, 50, 4473-7). The influence of oxyphenylbutazone and radiation therapy on cervical cancer has been studied. (Weppelmann and Monkemeier, *Gyn. Onc.*, 1984, 47, 196-9).

However, treatment with NSAIDs is limited by toxicity to normal tissue, particularly by ulcerations and bleeding in the gastrointestinal tract, ascribed to the inhibition of COX-1. Recently developed selective COX-2 inhibitors exert potent anti-inflammatory activity but cause fewer side effects.

Antiangiogenesis therapy has been used as an adjunct to chemotherapy, radiation therapy, or surgery. (Kumar and Armstrong, *Emerging Drugs* 1997, 2, 175-190). Recently, it was reported that the combination of radiation with antiangiogenic

-11-

compounds produces an additive effect on the growth of human tumor xenografts (Gorski et al., *Cancer Res.* 1998; 58, 5686-9).

COX-2 inhibitors have been described for the treatment of cancer (WO98/16227 and WO98/22101) and for the treatment of tumors (EP 927,555). Celecoxib, a specific inhibitor of COX-2, exerted a potent inhibition of fibroblast growth factor-induced corneal angiogenesis in rats. (Masferrer et al., *Proc. Am. Assoc. Cancer Research* 1999, 40, 396). COX-2 specific inhibitors prevent angiogenesis in experimental animals, but their efficacy in enhancing *in vivo* tumor response to radiation has not been established.

15

Brief Description of the Drawings

Fig. 1 shows the effect of a COX-2 inhibitor (4-[5-(4-chlorophenyl)-3-trifluoromethyl-1H-pyrazol-1-yl]benzenesulfonamide) on tumor growth.

20

Fig. 2 shows the effect of a COX-2 inhibitor (4-[5-(4-chlorophenyl)-3-trifluoromethyl-1H-pyrazol-1-yl]benzenesulfonamide) in combination with local tumor irradiation on tumor growth.

25

Fig. 3 shows the effect of a COX-2 inhibitor on dose-dependent and radiation-induced delay in tumor growth.

Fig 4 shows the effect of a COX-2 inhibitor on tumor cure by radiation.

30

Detailed Description of the Invention

-12-

Treatment of a neoplasia disorder in a mammal in need of such treatment is provided by methods and combinations using radiation and a COX-2 inhibitor. The method comprises treating a mammal with a
5 therapeutically effective amount of a COX-2 inhibitor and a radiotherapeutic agent.

Specific inhibitors of COX-2 potentiate tumor response to radiation. Thus, COX-2 inhibitors improve the efficacy of radiotherapy.

10 The methods and combinations of the present invention may be used for the treatment of neoplasia disorders selected from the group consisting of acral lentiginous melanoma, actinic keratoses, adenocarcinoma, adenoid cystic carcinoma, adenomas,
15 adenosarcoma, adenosquamous carcinoma, astrocytic tumors, Bartholin gland carcinoma, basal cell carcinoma, bronchial gland carcinomas, capillary, carcinoids, carcinoma, carcinosarcoma, cavernous, cholangiocarcinoma, chondrosarcoma, choroid plexus
20 papilloma/carcinoma, clear cell carcinoma, cystadenoma, endodermal sinus tumor, endometrial hyperplasia, endometrial stromal sarcoma, endometrioid adenocarcinoma, ependymal, epitheloid, Ewing's sarcoma, fibrolamellar, focal nodular
25 hyperplasia, gastrinoma, germ cell tumors, glioblastoma, glucagonoma, hemangioblastomas, hemangioendothelioma, hemangiomas, hepatic adenoma, hepatic adenomatosis, hepatocellular carcinoma, insulinoma, intraepithelial neoplasia,
30 interepithelial squamous cell neoplasia, invasive squamous cell carcinoma, large cell carcinoma,

-13-

leiomyosarcoma, lentigo maligna melanomas, malignant melanoma, malignant mesothelial tumors, medulloblastoma, medulloepithelioma, melanoma, meningeal, mesothelial, metastatic carcinoma, mucoepidermoid carcinoma, neuroblastoma, neuroepithelial adenocarcinoma nodular melanoma, oat cell carcinoma, oligodendroglial, osteosarcoma, pancreatic polypeptide, papillary serous adenocarcinoma, pineal cell, pituitary tumors, plasmacytoma, pseudosarcoma, pulmonary blastoma, renal cell carcinoma, retinoblastoma, rhabdomyosarcoma, sarcoma, serous carcinoma, small cell carcinoma, soft tissue carcinomas, somatostatin-secreting tumor, squamous carcinoma, squamous cell carcinoma, submesothelial, superficial spreading melanoma, undifferentiated carcinoma, uveal melanoma, verrucous carcinoma, vipoma, well differentiated carcinoma, and Wilm's tumor.

The methods and compositions of the present invention provide one or more benefits. A combination of a COX-2 inhibitor with radiation therapy of the present invention are useful in treating neoplasia disorders. Preferably, the COX-2 inhibitor agent or agents and the radiation therapies of the present invention are administered in combination at a low dose, that is, at a dose lower than has been conventionally used in clinical situations for each of the individual components administered alone.

A benefit of the present invention is lowering the dose of the radiation therapies administered to

-14-

a mammal to decrease the incidence of adverse effects associated with higher dosages.

By lowering the incidence of adverse effects, an improvement in the quality of life of a patient
5 undergoing treatment for cancer is achieved. Further benefits of lowering the incidence of adverse effects include an improvement in patient compliance, and a reduction in the number of hospitalizations needed for the treatment of adverse
10 effects.

Alternatively, the methods and combination of the present invention can also maximize the therapeutic effect at higher doses.

The term "pharmaceutically acceptable" is used
15 herein to mean that the modified noun is appropriate for use in a pharmaceutical product.

Pharmaceutically acceptable cations include metallic ions and organic ions. More preferred metallic ions include, but are not limited to appropriate alkali
20 metal salts, alkaline earth metal salts and other physiological acceptable metal ions. Exemplary ions include aluminum, calcium, lithium, magnesium, potassium, sodium and zinc in their usual valences. Preferred organic ions include protonated tertiary
25 amines and quaternary ammonium cations, including in part, trimethylamine, diethylamine, N,N'-dibenzylethylenediamine, chloroprocaine, choline, diethanolamine, ethylenediamine, meglumine (N-methylglucamine) and procaine. Exemplary
30 pharmaceutically acceptable acids include without limitation hydrochloric acid, hydrobromic acid,

phosphoric acid, sulfuric acid, methanesulfonic acid, acetic acid, formic acid, tartaric acid, maleic acid, malic acid, citric acid, isocitric acid, succinic acid, lactic acid, gluconic acid, glucuronic acid, pyruvic acid oxalacetic acid, fumaric acid, propionic acid, aspartic acid, glutamic acid, benzoic acid, and the like.

Also included in the combination of the invention are the prodrug, isomers and tautomers of the described compounds and the pharmaceutically-acceptable salts thereof. Illustrative pharmaceutically acceptable salts are prepared from formic, acetic, propionic, succinic, glycolic, gluconic, lactic, malic, tartaric, citric, ascorbic, glucuronic, maleic, fumaric, pyruvic, aspartic, glutamic, benzoic, anthranilic, mesylic, stearic, salicylic, p-hydroxybenzoic, phenylacetic, mandelic, embonic (pamoic), methanesulfonic, ethanesulfonic, benzenesulfonic, pantothenic, toluenesulfonic, 2-hydroxyethanesulfonic, sulfanilic, cyclohexylaminosulfonic, algenic, β -hydroxybutyric, galactaric and galacturonic acids.

Suitable pharmaceutically-acceptable base addition salts of compounds of the present invention include metallic ion salts and organic ion salts. More preferred metallic ion salts include, but are not limited to appropriate alkali metal (group Ia) salts, alkaline earth metal (group IIa) salts and other physiological acceptable metal ions. Such salts can be made from the ions of aluminum, calcium, lithium, magnesium, potassium, sodium and

-16-

zinc. Preferred organic salts can be made from tertiary amines and quaternary ammonium salts, including in part, trimethylamine, diethylamine, N,N'-dibenzylethylenediamine, chloroprocaine, choline, diethanolamine, ethylenediamine, meglumine (N-methylglucamine) and procaine. All of the above salts can be prepared by those skilled in the art by conventional means from the corresponding compound of the present invention.

10 A COX-2 inhibitor of the present invention can be formulated as a pharmaceutical composition. Such a composition can then be administered orally, parenterally, by inhalation spray, rectally, or topically in dosage unit formulations containing
15 conventional nontoxic pharmaceutically acceptable carriers, adjuvants, and vehicles as desired. Topical administration can also involve the use of transdermal administration such as transdermal patches or iontophoresis devices. The term
20 parenteral as used herein includes subcutaneous injections, intravenous, intramuscular, intrasternal injection, or infusion techniques. Formulation of drugs is discussed in, for example, Hoover, John E., Remington's Pharmaceutical Sciences, Mack Publishing
25 Co., Easton, Pennsylvania; 1975 and Liberman, H.A. and Lachman, L., Eds., Pharmaceutical Dosage Forms, Marcel Decker, New York, N.Y., 1980.

Injectable preparations, for example, sterile injectable aqueous or oleaginous suspensions can be
30 formulated according to the known art using suitable dispersing or wetting agents and suspending agents.

-17-

The sterile injectable preparation can also be a sterile injectable solution or suspension in a nontoxic parenterally acceptable diluent or solvent, for example, as a solution in 1,3-butanediol. Among
5 the acceptable vehicles and solvents that can be employed are water, Ringer's solution, and isotonic sodium chloride solution. In addition, sterile, fixed oils are conventionally employed as a solvent or suspending medium. For this purpose any bland
10 fixed oil can be employed including synthetic mono- or diglycerides. In addition, fatty acids such as oleic acid find use in the preparation of injectables. Dimethyl acetamide, surfactants including ionic and non-ionic detergents,
15 polyethylene glycols can be used. Mixtures of solvents and wetting agents such as those discussed above are also useful.

Suppositories for rectal administration of the drug can be prepared by mixing the drug with a
20 suitable nonirritating excipient such as cocoa butter, synthetic mono- di- or triglycerides, fatty acids and polyethylene glycols that are solid at ordinary temperatures but liquid at the rectal temperature and will therefore melt in the rectum
25 and release the drug.

Solid dosage forms for oral administration can include capsules, tablets, pills, powders, and granules. In such solid dosage forms, the compounds of this invention are ordinarily combined with one
30 or more adjuvants appropriate to the indicated route of administration. If administered per os, a

-18-

contemplated aromatic sulfone hydroximate inhibitor compound can be admixed with lactose, sucrose, starch powder, cellulose esters of alkanolic acids, cellulose alkyl esters, talc, stearic acid, magnesium stearate, magnesium oxide, sodium and calcium salts of phosphoric and sulfuric acids, gelatin, acacia gum, sodium alginate, polyvinylpyrrolidone, and/or polyvinyl alcohol, and then tableted or encapsulated for convenient administration. Such capsules or tablets can contain a controlled-release formulation as can be provided in a dispersion of active compound in hydroxypropylmethyl cellulose. In the case of capsules, tablets, and pills, the dosage forms can also comprise buffering agents such as sodium citrate, magnesium or calcium carbonate or bicarbonate. Tablets and pills can additionally be prepared with enteric coatings.

For therapeutic purposes, formulations for parenteral administration can be in the form of aqueous or non-aqueous isotonic sterile injection solutions or suspensions. These solutions and suspensions can be prepared from sterile powders or granules having one or more of the carriers or diluents mentioned for use in the formulations for oral administration. A contemplated COX-2 inhibitor compound can be dissolved in water, polyethylene glycol, propylene glycol, ethanol, corn oil, cottonseed oil, peanut oil, sesame oil, benzyl alcohol, sodium chloride, and/or various buffers.

-19-

Other adjuvants and modes of administration are well and widely known in the pharmaceutical art.

Liquid dosage forms for oral administration can include pharmaceutically acceptable emulsions, solutions, suspensions, syrups, and elixirs containing inert diluents commonly used in the art, such as water. Such compositions can also comprise adjuvants, such as wetting agents, emulsifying and suspending agents, and sweetening, flavoring, and perfuming agents.

The amount of active ingredient that can be combined with the carrier materials to produce a single dosage form varies depending upon the mammalian host treated and the particular mode of administration.

The term "treatment" refers to any process, action, application, therapy, or the like, wherein a mammal, including a human being, is subject to medical aid with the object of improving the mammal's condition, directly or indirectly.

The term "inhibition," in the context of neoplasia, tumor growth or tumor cell growth, may be assessed by delayed appearance of primary or secondary tumors, slowed development of primary or secondary tumors, decreased occurrence of primary or secondary tumors, slowed or decreased severity of secondary effects of disease, arrested tumor growth and regression of tumors, among others. In the extreme, complete inhibition, is referred to herein as prevention.

The term "prevention" includes either preventing the

-20-

onset of clinically evident neoplasia altogether or preventing the onset of a preclinically evident stage of neoplasia in individuals at risk. Also intended to be encompassed by this definition is the prevention of
5 initiation for malignant cells or to arrest or reverse the progression of premalignant cells to malignant cells. This includes prophylactic treatment of those at risk of developing the neoplasia.

Angiogenesis is an attractive therapeutic
10 target because it is a multi-step process that occurs in a specific sequence, thus providing several possible targets for drug action. Examples of agents that interfere with several of these steps include specific COX-2 inhibitors, that prevent the
15 growth of cells that form new blood vessels.

The phrase "therapeutically-effective" is intended to qualify the amount of each agent that will achieve the goal of improvement in neoplastic disease severity and the frequency of incidence over
20 treatment of each agent by itself, while avoiding adverse side effects typically associated with alternative therapies. A "therapeutic effect" relieves to some extent one or more of the symptoms of a neoplasia disorder. In reference to the
25 treatment of a cancer, a therapeutic effect refers to one or more of the following: 1) reduction in the number of cancer cells; 2) reduction in tumor size; 3) inhibition (i.e., slowing to some extent, preferably stopping) of cancer cell infiltration
30 into peripheral organs; 4) inhibition (i.e., slowing to some extent, preferably stopping) of tumor

-21-

metastasis; 5) inhibition, to some extent, of tumor growth; 6) relieving or reducing to some extent one or more of the symptoms associated with the disorder; and/or 7) relieving or reducing the side effects associated with the administration of anticancer agents. "Therapeutic effective amount" is intended to qualify the amount required to achieve a therapeutic effect. The phrases "low dose" or "low dose amount", in characterizing a therapeutically effective amount of the COX-2 inhibitor and the radiation or therapy in the combination therapy, defines a quantity of such therapy, or a range of quantity of such therapy, that is capable of diminishing the neoplastic disease while reducing or avoiding one or more radiation-induced side effects, such as myelosuppression, cardiac toxicity, skin erythema and desquamation, alopecia, inflammation or fibrosis.

The phrase "adjunctive therapy" includes agents such as those, for example, that reduce the toxic effect of anticancer drugs, e.g., bone resorption inhibitors, cardioprotective agents; prevent or reduce the incidence of nausea and vomiting associated with chemotherapy, radiotherapy or operation; or reduce the incidence of infection associated with the administration of myelosuppressive anticancer drugs.

The phrase a "radiotherapeutic agent" refers to the use of electromagnetic or particulate radiation in the treatment of neoplasia. Examples of radiotherapeutic agents are provided in, but not

-22-

limited to, radiation therapy and is known in the art (Hellman, Principles of Radiation Therapy, Cancer, in Principles and Practice of Oncology, 248-75 (Devita et al., ed., 4th ed., v1, 1993)).

5 The phrase "COX-2 inhibitor" includes agents that specifically inhibit a class of enzymes, the COX-2 enzyme. Preferably, it includes compounds which have a COX-2 IC₅₀ of less than about 1.0 μ M, and more preferably of less than about 0.1 μ M, and
10 also have a selectivity ratio of COX-2 inhibition over COX-1 inhibition of at least 50, and more preferably of at least 100. Examples of COX-2 inhibitors are provided in, but not limited to, Table Nos. 1 and 2.

15 The phrase "combination therapy" (or "co-therapy") is embraces administration of each agent or therapy in a sequential manner in a regimen that will provide beneficial effects of the combination, and co-administration of these agents or therapies
20 in a substantially simultaneous manner, such as in a single capsule having a fixed ratio of these active agents or in multiple, separate capsules for each agent. Combination therapy also includes combinations where the individual elements may be
25 administered at different times and/or by different routes but which act in combination to provide a beneficial effect by co-action of pharmacokinetic and pharmacodynamic effect of each agent or tumor treatment approaches of the combination therapy.

30 Generally, radiation therapy has been combined temporally with chemotherapy to improve the outcome

-23-

of treatment. There are various terms to describe the temporal relationship of administering radiation therapy and chemotherapy, and the following examples are the preferred treatment regimens and are

5 generally known by those skilled in the art and are provided for illustration only and are not intended to limit the use of other combinations.

"Sequential" radiation therapy and chemotherapy refers to the administration of chemotherapy and
10 radiation therapy separately in time in order to allow the separate administration of either chemotherapy or radiation therapy. "Concomitant" radiation therapy and chemotherapy refers to the administration of chemotherapy and radiation therapy
15 on the same day. Finally, "alternating" radiation therapy and chemotherapy refers to the administration of radiation therapy on the days in which chemotherapy would not have been administered if it was given alone.

20 Radiation therapy is based on the principle that high-dose radiation delivered to a target area will result in the death of reproductive cells in both tumor and normal tissues. The radiation dosage regimen is generally defined in terms of radiation
25 absorbed dose (rad), time and fractionation, and must be carefully defined by the oncologist. The amount of radiation a patient receives will depend on various consideration but the two most important considerations are the location of the tumor in
30 relation to other critical structures or organs of

-24-

the body, and the extent to which the tumor has spread.

The referenced tables provided herein, provides non-exhaustive examples of each subtype that may be
5 used in combinations and methods of the present invention.

Table 1: COX-2 Inhibitors

Compound	Trade Name	Company	Mode of Action	Reference	Dosage	Toxicity	Cancer Indication
lornoxicam	Safen	Roche Holding AG	Cyclooxygenase inhibitor			Cynomolgus monkeys: 1-2 mg/kg/day orally for six weeks	
1,5-Diphenyl-3-substituted pyrazoles		Fujisawa Pharmaceutical Co Ltd	Cyclooxygenase 2 inhibitor	WO9713755			
radicicol		Scripps Research Institute	Tyrosine kinase inhibitor, Cyclooxygenase 2 modulator, IL-1 antagonist, TNF alpha antagonist	WO9625928 Kwon et al (Cancer Res (1992) 52 6296)			
N-benzyl-3-indoleacetic acids		Merck & Co Inc	Cyclooxygenase inhibitor, Anticancer	US-5510368			
GB-02283745		Merck & Co Inc	Cyclooxygenase 2 inhibitor				
TP-72		Dartmouth Medical School	NO synthesis inhibitor, Cyclooxygenase 2 inhibitor	Cancer Res 1998 58 4717 -723			

Table 1: COX-2 Inhibitors						
Indene inhibitors of cox-2	American Home Products Corp	Cyclooxygenase 2 inhibitor	WO9821195			
carbocyclic diarylethylene derivatives	Bristol- Myers Squibb	Cyclooxygenase 2 inhibitor	WO9805643		Rat: >300 mg/kg po	
1,2-Diarylindole	Bristol- Myers Squibb	Cyclooxygenase 2 inhibitor	WO9805639			
1,2- Bisarylcyclobutene derivatives	Merck & Co Inc	Cyclooxygenase 2 inhibitor	WO9736863			
Novel stilbene derivatives prodrugs	Merck & Co Inc	Cyclooxygenase 2 inhibitor	WO- 9728121			
2,4-Diphenylbutenoic acid prodrugs	Merck & Co Inc		WO- 9728120			
1-(4-chlorobenzoyl)- 3-[4-(4-fluoro- phenyl)thiazol-2- ylmethyl]-5-methoxy- 2-methyl-indole	Abbott	Cyclooxygenase 2 inhibitor				
	Merck & Co	Cyclooxygenase 2 inhibitor	WO9518799 WO9608482 WO9606840 WO9621667 WO9636623 WO9744027			Colon cancer
Sulfonamide substi- tuted diarylthiazole		Cyclooxygenase 2 inhibitor				

Table 1: COX-2 Inhibitors						
	GR-253035	Glaxo Wellcome	Cyclooxygenase 2 inhibitor			Chronic inflammatory pain
4-(4-cyclohexyl-2-methyloxazol-5-yl)-2-fluorobenzene-sulfonamide	JTE-522	Japan Tobacco	Cyclooxygenase 2 inhibitor	WO9619463		Pain
5,6-diarylthiazolo[3,2-B][1,2,4]triazolo	L-768277	Merck & Co	Cyclooxygenase 2 inhibitor			
	L-783003	Merck & Co	Cyclooxygenase 2 inhibitor			
	MK-966	Merck & Co	Cyclooxygenase 2 inhibitor		12.5-100 mg po	
indolalkanoic acid		Merck & Co	Cyclooxygenase 2 inhibitor	WO9637467	200 mg/kg/day	
1-Methylsulfonyl-4-[1,1-dimethyl-4-(4-fluorophenyl)-cyclopenta-2,4-dien-3-yl]benzene		Monsanto	Cyclooxygenase 2 inhibitor	WO9530656 WO9530652 WO9638418 WO9638442		
4,4-dimethyl-2-phenyl-3-[4-(methylsulfonyl)-phenyl]cyclobutenone; 1,2-diarylcyclobutenes		Merck & Co	Cyclooxygenase 2 inhibitor			
		Chugai	Cyclooxygenase 2 inhibitor	WO 9730030		

Table 1: COX-2 Inhibitors						
2-(4-methoxyphenyl)-4-methyl-1-(4-sulfamoylphenyl)-pyrrole; 1,2-diphenylpyrrole derivatives	Sankyo	Cyclooxygenase 2 inhibitor	EP 799823			
tetrahydrofuranones	Bristol-Myers Squibb	Cyclooxygenase 2 inhibitor	WO 9737984			
N-[5-(4-fluorophenoxy)]thiophene-2-methanesulfonamide	RWJ-63556 Johnson & Johnson	5 Lipoxygenase inhibitor; Cyclooxygenase 2 inhibitor; Leucotriene B4 antagonist				
5(E)-(3,5-di-tert-butyl-4-hydroxy)benzylidene-2-ethyl-1,2-isothiazolidine-1,1-dioxide	S-2474 Shionogi	Prostaglandin E2 antagonist; Leucotriene B4 antagonist; Cyclooxygenase 2 inhibitor	EP 595546			
	SC-57666 Monsanto	Cyclooxygenase 2 inhibitor				
3-formylamino-7-methylsulfonylamino-6-phenoxy-4H-1-benzopyran-4-one	T-614 Toyama	Cyclooxygenase 2 inhibitor; Interleukin 1b antagonist; Interleukin 6 antagonist	DE 3834204			

Table 1: COX-2 Inhibitors						
	celecoxib; Celebrex SC-58635; YM-177	Monsanto	Cyclooxygenase 2 inhibitor			
4-(5-(4-methylphenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl)-Benzenesulfonamide						
2H-1,2-Benzothiazine-3-carboxamide, 4-hydroxy-2-methyl-N-(5-methyl-2-thiazolyl)-, 1,1-dioxide-	meloxicam; Mobic; Mobec; Moricox; Mobicox; Movalis;	Boehringer Ingelheim	Cyclooxygenase 2 inhibitor; Prostaglandin synthase inhibitor	US 4233299	15-30 mg/day	
Methanesulfonamide, N-(4-nitro-2-phenoxyphenyl)	nimesulide	Helsinn	Cyclooxygenase 2 inhibitor; Prostaglandin synthase inhibitor	US 3840597		
Methanesulfonamide, N-(4-nitro-2-phenoxyphenyl)	nimesulide, Poli	Poli	Cyclooxygenase 2 inhibitor			
	valdecoxib	Monsanto	COX-2 inhibitor	US 5,633,272		
	CS-502	Sankyo	COX-2 inhibitor			
	MK-663	Merck	COX-2 inhibitor			

Table 2: Preferred COX-2 Inhibitors			
Patent	Publication/issue/filing Dates	Oncology Indication	Dosage of Preferred Compounds
US 5776967 A	980707	colorectal cancer	
WO 9821195 A1	980522	colorectal cancer	
WO 9804527 A1	980205	colorectal cancer	0.01-100 mg/kg/day orally or parenterally
WO 9825896 A1	980618		
US 5760068 A	980602		
WO 9822101 A2	980528	colorectal cancer	
WO 9816227 A1	980423	antiangiogenic	
US 5719163 A	980217	epithelial cell neoplasia	
WO 9806708 A1	980219		
WO 9738986 A1	971023		
US 5663180 A	970902		
WO 9729776 A1	970821		
WO 9729774 A1	970821	cancer	0.1-2000 (preferably 0.5- 500, especially 1-100) mg/kg/day orally, intravascularly, intraperitoneally, subcutaneously, or intramuscularly, or topically.
WO 9729775 A1	970821	cancer	0.1-2000 (preferably 0.5- 500, especially 1-100) mg/kg/day orally, intravascularly, intraperitoneally, subcutaneously, or intramuscularly, or topically.

Table 2: Preferred COX-2 Inhibitors				
Patent	Publication/issue/filing Dates	Oncology Indication	Dosage of Preferred Compounds	
WO 9727181 A1	970731			
WO 9714679 A2	970424			
WO 9711704 A1	970403			
US 5616601 A	970401			
WO 9641645 A1	961227			
WO 9641625 A1	961227	colorectal cancer	0.01-100 mg/kg/day oral, topical or parenteral.	
WO 9641626 A1	961227			
WO 9638442 A1	961205			
WO 9638418 A1	961205	colorectal cancer	0.1-100 (preferably 0.1- 10) mg/kg/day, orally, injection, topically, or transdermally.	
WO 9625405 A1	960822			
WO 9624585 A1	960815			
WO 9609293 A1	960328			
WO 9603387 A1	960208			
US 5739166	980414	colorectal cancer	0.01-100 (preferably 0.1- 10 mg/kg/day, orally, topical or intramuscular	
WO 9616934 A1	960606			
WO 9603388 A1	960208			
WO 9603392 A1	960208			
WO 9530652 A1	951116			
WO 9515316 A1	950608			
WO 9515318 A1	950608			
US 5393790 A	950228			
US 5380738	950110	colorectal cancer	0.01-100 (pref. 0.1-50) mg/kg/day, oral, parental, or topical	
WO 9427980 A1	941208			

Table 2: Preferred COX-2 Inhibitors			
Patent	Publication/issue/filing Dates	Oncology Indication	Dosage of Preferred Compounds
US 5719163 WO 9427980 A1	980217 941208	colorectal cancer	0.01-100 (pref. 0.1-50) mg/kg/day, oral, parental, or topical
US 5420343 A	950530		
US 5434178	950718		
US 5466823	951114		
US 5521207	960528		
US 5563165	961008		
US 5508426	960416		
US 5504215	960402		
US 5516907	960514		
US 5510496	960423		
US 5753688	980519		
US 5753688	980519		
US 5736579 WO 9521817 A1	980407 950817	colorectal cancer	
SOFR 95/1107	960424		
US 5668161	970916		
US 5418254	950523		
US 5576339	961119		colorectal cancer
US 5672626	970930		
US 5670510	970923		
US 5686470 WO 9624584 A1	971111 960815	colorectal cancer	0.01-100 (preferably 0.1- 10) mg/kg/ day
US 5580985 WO 9603385 A1	961203 960208		0.01-100 (preferably 0.1- 10) mg/kg/ day
US 5756530 WO 9603385 A1	980526 960208		0.01-100 (preferably 0.1- 10) mg/kg/ day
US 5486534 A	960123		

Table 2: Preferred COX-2 Inhibitors				
Patent	Publication/issue/filing Dates	Oncology Indication	Dosage of Preferred Compounds	
WO 9603385 A1	960208			
US 5620999	970415	colorectal cancer		
WO 9603387 A1	960208		0.01-100 (preferably 0.5-20) mg/kg/ day, oral, intravascular, intraperitoneal, subcutaneous, intramuscular, or topical	
US 5696143	970912			
WO 960923 A1	960328			
US 5547975	960820			
WO 9609304 A1	960328			
US 5565482	961015			
WO 9609304 A1	960328			
US 5670532	970923			
WO 9609304 A1	960328			
US 5596008	970121			
WO 9624585 A1	960815			
US 5643933	970701			
WO 9638442 A1	961205			
US 08/541850	951010			
US 08/540522	951010			
PCT US97/05497	970411			
US 5935990				
PCT US98/07677	980418			
US 5380738	950110			
EPO 95909447.5	950207			
EPO 95928164.3	950727			
AT 9700165 A	980415			
AU 9719132 A	970814			

Table 2: Preferred COX-2 Inhibitors				
Patent	Publication/issue/filing Dates	Oncology Indication	Dosage of Preferred Compounds	
CA 2164559 AA	960610			
DE 19518421 A1	961121			
DE 19533643 A1	970313		0.01-1000 mg/day orally or parenterally	
DE 19533644 A1	970313		0.01-1000 mg/day orally or parenterally	
EP 714895 A1	960605		0.001-150 (preferably 5- 20) mg/kg/day	
EP 799823 A1	971008			
EP 832652 A1	980401	adenocarcinoma		
EP 846689 A1	980610	metastasis inhibitors		
EP 850894 A1	980701			
EP 850895 A1	980701			
FR 2751966 A1	980206		Oral or parenteral 0.1- 100 mg/kg/day.	
GB 2283745 A1	950517			
GB 2294879 A1	960515			
GB 2319772 A	980603	cancer		
DE 19753463 A1	980604		50 mg to 5 g/day (preferably 100-500 mg/day in 1 to 3 doses)	
GB 2320715 A	980701			
JP 08157361 A2	960618			
JP 09048769 A2	970218			
JP 09071656 A2	970318			
JP 09071657 A2	970318			
JP 09077664 A2	970325			
JP 09194354 A2	970729	ulcerative colitis		
JP 09221422 A2	970826			
JP 10175861 A2	980630	metastasis inhibitors		

Table 2: Preferred COX-2 Inhibitors				
Patent	Publication/issue/filing Dates	Oncology Indication	Dosage of Preferred Compounds	
US 5474995 A	951212			
US 5510368 A	960423		0.1-140 mg/kg/day or 0.5-7 g/patient, oral, topical, perenteral, inhalation, rectal	
US 5604260 A	970218			
US 5616458 A	970401			
US 5633272 A	970527			
US 5663195 A	970902		0.01-100 mg/kg/day; 0.5mg-6g/day	
US 5677318 A	971014	inhibitor of cellular neoplastic transformations and metastatic tumor growth; treatment of proliferative disorders, e.g., tumor angiogenesis		
US 5677318 A	971014			
US 5681842 A	971028			
US 5686460 A	971111			
US 5733909 A	980331			
US 5783597 A	980721			
WO 9413635 A1	940623			
WO 9414977 A1	940707			
WO 9420480 A1	940915	Inhibition of neoplastic transformations and metastatic tumor growth	0.01-140 mg/kg/day administered orally.	
WO 9426731 A1	941124			
WO 9500501 A2	950105			
WO 9511883 A1	950504	colorectal cancer		

Table 2: Preferred COX-2 Inhibitors

Patent	Publication/issue/filing Dates	Oncology Indication	Dosage of Preferred Compounds
WO 9606840 A1	960307		
WO 9608482 A1	960321		
WO 9611676 A1	960425		0.01-140 mg/kg/day
WO 9612483 A1	960502	inhibition of nitric oxide formation	
WO 9613483 A1	960509	Inhibition of neoplastic transformation and metastatic tumor growth	0.01-140 mg/kg/day
WO 9619462 A1	960627		0.01-1000 (preferably 0.1-300)mg/day p.o. or parenterally
WO 9619462 A1	960627		
WO 9619463 A1	960627		
WO 9619463 A1	960627		0.1-1000 (preferably 1- 300) mg/day p.o. or parenterally
WO 9619469 A1	960627		
WO 9621667 A1	960718		
WO 9623786 A1	960808	osteosarcoma	0.01-140 mg/kg/day, orally, rectal, injection, topical.
WO 9624604 A1	960815		
WO 9625405 A1	960822		
WO 9625928 A1	960829		
WO 9626921 A1	960906		
WO 9631509 A1	961010		
WO 9636617 A1	961121	colorectal cancer	
WO 9636623 A1	961121		
WO 9637467 A1	961128		0.01-140 mg/kg/day,

Table 2: Preferred COX-2 Inhibitors			
Patent	Publication/issue/filing Dates	Oncology Indication	Dosage of Preferred Compounds
			orally, topical, parenteral, rectal or inhalation.
WO 9637469 A1	961128		
WO 9639144 A1	961212		
WO 9640143 A1	961219		
WO 9641626 A1	961227	colorectal cancer	
WO 9703667 A1	970206	colonic adenomas; colonic adenocarcinomas	
WO 9703953 A1	970206		0.01-1000 mg p.o or i.p. (oral, parenteral, rectal, topical or transdermal)
WO 9709977 A1	970320		
WO 9710840 A1	970327		
WO 9711701 A1	970403	cancer	
WO 9711701 A1	970403		
WO 9713755 A1	970417	cancer	
WO 9713767 A1	970417		
WO 9714691 A1	970424		
WO 9716435 A1	970509		
WO 9725045 A1	970717		0.1-80 mg/kg/day orally or parenterally
WO 9725046 A1	970717		
WO 9725047 A1	970717		0.1-80 mg/kg/day oral or parenteral
WO 9725048 A1	970717	pulmonary sarcoiiosis	0.1-80 mg/kg/day oral or parenteral
WO 9727181 A1	970731	colorectal cancer	

Table 2: Preferred COX-2 Inhibitors

Patent	Publication/issue/filing Dates	Oncology Indication	Dosage of Preferred Compounds
WO 9728120 A1	970807		
WO 9728121 A1	970807		0.01-140 mg/kg/day
WO 9730030 A1	970821		3-150 mg/hg p.o. or 1-50 mg/hg parenterally
WO 9731631 A1	970904		
WO 9734882 A1	970925	colorectal cancer	
WO 9736497 A2	971009	antineoplastic; prostate, renal, colon, breast, or cervical cancer	
WO 9736863 A1	971009		0.01-140 mg/kg/day (oral, topical, rectal, parenteral, inhalation)
WO 9737984 A1	971016		Orally 300 mg/kg/day
WO 9738686 A1	971023	regulation of COX-II expression	
WO 9740012 A1	971030		
WO 9744027 A1	971127		Orally 2.5-250 mg/day (preferably 12.5-20 mg/day)
WO 9744028 A1	971127		
WO 9745420 A1	971204		
WO 9746524 A1	971211		
WO 9746532 A1	971211		0.08-15.0 mg/kg/day (preferably 0.16-3.0 mg/kg/day)
WO 9800416 A1	980108		
WO 9803484 A1	980129	Inhibit neoplastic formation and metastatic tumor growth	Orally 0.01-140 mg/kg/day (preferably 0.5-7 mg/kg/day)
WO 9805639 A1	980212		

Table 2: Preferred COX-2 Inhibitors				
Patent	Publication/issue/filing Dates	Oncology Indication	Dosage of Preferred Compounds	
WO 9806715 A1	980219			
WO 9807425 A1	980226		0.01-80 mg/kg/day oral or parenteral; topical 0.1- 150 mg/day in 1-4 doses.	
WO 9807714 A1	980226			
WO 9811080 A1	980319		1-1000 mg/day (oral, rectal, topical); 0.1-500 mg/day parenteral.	
WO 9815528 A1	980416			
WO 9816227 A1	980423			
WO 9817292 A1	980430			
WO 9821195 A1	980522	tumor angiogenesis; colorectal cancers metastasis		
WO 9822101 A2	980528			
WO 9822104 A2	980528			
WO 9822442 A2	980528			
WO 9822457 A1	980528			
WO 9824782 A2	980611			
ZA 9704806 A	980325	colon cancer	0.1-500 mg/kg/day administered orally	
WO98/57924				
WO98/39330				
WO98/41516				
WO98/46594				
WO98/47871				
WO98/47890				
WO99/18960				
WO99/23087				
WO99/24025				

Table 2: Preferred COX-2 Inhibitors			
Patent	Publication/issue/filing Dates	Oncology Indication	Dosage of Preferred Compounds
WO99/15503			
WO99/14195			
WO99/14194			
WO99/05104			
WO99/12930			
WO99/10332			
WO99/10331			
WO99/11605			
WO99/33796			
WO99/35130			
WO99/15505			
US 5,916,905			
US 5,830,911			
US 5,840,924			
US 5,849,943			
US 5,869,524			
US 5,869,524			
US 5,859,257			
US 5,859,036			
US 5,883,267			
US 5,863,946			
US 5,811,425			
US 5,908,858			
US 5,908,852			
US 5,919,809			
US 5,922,742			
WO 94/15932	21 July 1994		
WO 95/09238	6 April 1995		
WO 95/18799	13 July 1995		


Table 2: Preferred COX-2 Inhibitors			
Patent	Publication/issue/filing Dates	Oncology Indication	Dosage of Preferred Compounds
WO 96/06840	7 March 1996		
WO 96/37468	28 NOVEMBER 1996		
WO 96/42941	10 July 1996		
WO 98/43966	8 October 1998		
WO 98/41511	24 September 1998		
US 5,409,944	25 April 1995		
US 5,521,213	28 May 1996		
US 5,536,752	16 July 1996		
US 5,550,142	27 August 1996		
US 5,552,422	3 September 1996		
US 5,604,253	18 February 1997		
US 5,639,780	17 June 1997		
US 5,691,374	25 November 1997		
US 5,698,584	16 December 1997		
US 5,767,291	16 June 1998		
US 5,789,413	4 August 1998		
US 5,932,598	3 August 1999		
US 5,932,994	3 August 1999		

Preferred Combinations Generally


A preferred combination therapy consists essentially of a COX-2 inhibitor in combination with a radiotherapeutic agent.

5 Examples of COX-2 inhibitors that may be used in the combination therapy are provided in, but not limited to, Table No. 1. Preferred COX-2 inhibitors that may be used in the combination therapy are shown in Table No. 2. The most preferred COX-2
10 inhibitors are selected from the group consisting of:


1)




2)



3)



4)




15


20

-43-


5)




6)



7)




8)




5

9)




10)




10

-44-


11)



12)




13)




5


14)



15)




16)




-45-


17)




18)




5 19)




20)



21)




22)




10

23)




24)




-46-


25)




26)



27)




28)




5

29)




30)




-47-


31)



32)




33)




5


34)



35)




36)




-48-


37)




38)




39)




40)



41)




42)




10

43)



44)



and

COX-2 Inhibitors

Specific COX-2 inhibitors are useful for the treatment of cancer (WO98/16227) and in several animal models reduce angiogenesis driven by various growth factors (WO98/22101). Anti-angiogenesis was achieved with a COX-2 inhibitor in rats implanted with bFGF, vascular endothelium growth factor (VEGF) or carrageenan, proteins with well-known angiogenic properties. (Masferrer, et al., 89th Annual Meeting of the American Association for Cancer Research, March 1998.)

Dosage of COX-2 Inhibitors

Dosage levels of COX-2 inhibitors on the order of about 0.1 mg to about 10,000 mg of the active antiangiogenic ingredient compound are useful in the treatment of the above conditions, with preferred levels of about 1.0 mg to about 1,000 mg. The amount of active ingredient that may be combined with other anticancer agents to produce a single dosage form will vary depending upon the host treated and the particular mode of administration.

It is understood, however, that a specific dose level for any particular patient will depend upon a variety of factors including the activity of the specific compound employed, the age, body weight, general health, sex, diet, time of administration, rate of excretion, drug combination, and the severity of the particular disease being treated and form of administration.

-50-

Treatment dosages generally may be titrated to optimize safety and efficacy. Typically, dosage-effect relationships from in vitro initially can provide useful guidance on the proper doses for patient administration. Studies in animal models also generally may be used for guidance regarding effective dosages for treatment of cancers in accordance with the present invention. In terms of treatment protocols, it should be appreciated that the dosage to be administered will depend on several factors, including the particular agent that is administered, the route administered, the condition of the particular patient, etc. Generally speaking, one will desire to administer an amount of the compound that is effective to achieve a serum level commensurate with the concentrations found to be effective in vitro. Thus, where an compound is found to demonstrate in vitro activity at, e.g., 10 μ M, one will desire to administer an amount of the drug that is effective to provide about a 10 μ M concentration in vivo. Determination of these parameters are well within the skill of the art.

These considerations, as well as effective formulations and administration procedures are well known in the art and are described in standard textbooks.

Administration Regimen

Any effective treatment regimen can be utilized and readily determined and repeated as necessary to effect treatment. In clinical practice, the

-51-

compositions containing a COX-2 inhibitor alone or in combination with other therapeutic agents are administered in specific cycles until a response is obtained.

5 For patients who initially present without advanced or metastatic cancer, a COX-2 inhibitor in combination with radiation therapy, is used as a continuous post-treatment therapy in patients at risk for recurrence or metastasis (for example, in
10 adenocarcinoma of the prostate, risk for metastasis is based upon high PSA, high Gleason's score, locally extensive disease, and/or pathological evidence of tumor invasion in the surgical specimen). The goal in these patients is to inhibit
15 the growth of potentially metastatic cells from the primary tumor during surgery and inhibit the growth of tumor cells from undetectable residual primary tumor.

 For patients who initially present with
20 advanced or metastatic cancer, a COX-2 inhibitor in combination with radiation therapy of the present invention is used as a continuous supplement to, or possible replacement for hormonal ablation. The goal in these patients is to slow or prevent tumor cell
25 growth from both the untreated primary tumor and from the existing metastatic lesions.

 The following discussion highlights some agents in this respect, which are illustrative, not limitative. A wide variety of other effective agents
30 also may be used.

-52-

Colorectal Cancer

The preferred combination therapy for the treatment of colorectal cancer is surgery, followed by a regimen of one or more chemotherapeutic agents, 5 cycled over a one year time period. In the treatment of colorectal cancer, radiation alone or in combination with surgery and/or chemotherapeutic agents is often used. Preferred chemotherapeutic agents include fluorouracil, and Levamisole. 10 Preferably, fluorouracil and Levamisole are used in combination.

Prostate Cancer

Current therapies for prostate cancer focus 15 upon reducing levels of dihydrotestosterone to decrease or prevent growth of prostate cancer. Radiation alone or in combination with surgery and/or chemotherapeutic agents is often used.

20 Pancreas Cancer

Preferred combinations of therapy for the treatment of non-metastatic adenocarcinoma include the use of preoperative biliary tract decompression (patients presenting with obstructive jaundice); 25 surgical resection, including standard resection, extended or radial resection and distal pancreatectomy (tumors of body and tail); adjuvant radiation; and chemotherapy. For the treatment of metastatic adenocarcinoma, the preferred 30 chemotherapy consists of 5-fluorouracil, followed weekly cisplatin therapy.

-53-

Lung Cancer

In many countries including Japan, Europe and America, the number of patients with lung cancer is fairly large and continues to increase year after year and is the most frequent cause of cancer death in both men and women. Although there are many potential causes for lung cancer, tobacco use, and particularly cigarette smoking, is the most important. Additionally, etiologic factors such as exposure to asbestos, especially in smokers, or radon are contributory factors. Also occupational hazards such as exposure to uranium have been identified as an important factor. Finally, genetic factors have also been identified as another factor that increase the risk of cancer.

Lung cancers can be histologically classified into non-small cell lung cancers (e.g. squamous cell carcinoma (epidermoid), adenocarcinoma, large cell carcinoma (large cell anaplastic), etc.) and small cell lung cancer (oat cell). Non-small cell lung cancer (NSCLC) has different biological properties and responses to chemotherapeutics from those of small cell lung cancer (SCLC). Thus, chemotherapeutic formulas and radiation therapy are different between these two types of lung cancer.

Non-Small Cell Lung Cancer

Where the location of the non-small cell lung cancer tumor can be easily excised (stage I and II disease) surgery is the first line of therapy and

-54-

offers a relatively good chance for a cure.
However, in more advanced disease (stage IIIa and greater), where the tumor has extended to tissue beyond the bronchopulmonary lymph nodes, surgery may
5 not lead to complete excision of the tumor. In such cases, the patient's chance for a cure by surgery alone is greatly diminished. Where surgery will not provide complete removal of the NSCLC tumor, other types of therapies must be utilized.

10 Today radiation therapy is the standard treatment to control unresectable or inoperable NSCLC. Improved results have been seen when radiation therapy has been combined with chemotherapy, but gains have been modest and the
15 search continues for improved methods of combining modalities. A preferred course of treatment for a patient undergoing radiation therapy for NSCLC will be a treatment schedule over a 5 to 6 week period, with a total dose of 50 to 60 Gy administered to the
20 patient in a single daily fraction of 1.8 to 2.0 Gy, 5 days a week. A Gy is an abbreviation for Gray and refers to 100 rad of dose.

However, as NSCLC is a systemic disease, and radiation therapy is a local modality, radiation
25 therapy as a single line of therapy is unlikely to provide a cure for NSCLC, at least for those tumors that have metastasized distantly outside the zone of treatment. Thus, the use of radiation therapy with other modality regimens have important beneficial
30 effects for the treatment of NSCLC.

-55-

It is reported that advanced non-small cell lung cancers do not respond favorably to single-agent chemotherapy and useful therapies for advanced inoperable cancers have been limited. (J. Clin. Oncol. 1992, 10, 829-838).

Japanese Patent Kokai 5-163293 refers to 16-membered-ring macrolide antibiotics as a drug delivery carrier capable of transporting anthoracycline-type anticancer drugs into the lungs for the treatment of lung cancers. However, the macrolide antibiotics specified herein are disclosed to be only a drug carrier, and there is no reference to the therapeutic use of macrolides against non-small cell lung cancers.

WO 93/18652 refers to the effectiveness of the specified 16-membered-ring macrolides such as bafilomycin, etc. in treating non-small cell lung cancers, but they have not yet been clinically practicable.

Pharmacology, vol. 41, pp. 177-183 (1990) describes that a long-term use of erythromycin increases productions of interleukins 1, 2 and 4, all of which contribute to host immune responses, but there is no reference to the effect of this drug on non-small cell lung cancers.

Tetragenesis, Carcinogenesis, and Mutagenesis, vol. 10, pp. 477-501 (1990) describes that some of antimicrobial drugs can be used as an anticancer agent, but does not refer to their application to non-small cell lung cancers.

-56-

In addition, interleukins are known to have an antitumor effect, but have not been reported to be effective against non-small cell lung cancers.

Any 14 - or 15-membered-ring macrolides have
5 not been reported to be effective against non-small cell lung cancers.

However, several chemotherapeutic agents have been shown to be efficacious against NSCLC. Preferred chemotherapeutic agents against NSCLC
10 include etoposide, carboplatin, methotrexate, 5-fluorouracil, epirubicin, doxorubicin, and cyclophosphamide. The most preferred chemotherapeutic agents active against NSCLC include cisplatin, ifosfamide, mitomycin C, epirubicin,
15 vinblastine, and vindesine.

Other agents that are under investigation for use against NSCLC include: camptothecins, a topoisomerase 1 inhibitor; navelbine (vinorelbine), a microtubule assembly inhibitor; taxol, inhibitor of
20 normal mitotic activity; gemcitabine, a deoxycytidine analogue; fotemustine, a nitrosourea compound; and edatrexate, a antifol.

The overall and complete response rates for NSCLC has been shown to increase with use of
25 combination chemotherapy as compared to single-agent treatment. Haskel, Chest. 1991, 99: 1325; Bakowsk, Cancer Treat. Rev. 1983, 10:159; Joss, Cancer Treat. Rev. 1984, 11: 205.

30

Small Cell Lung Cancer

-57-

Approximately 15 to 20 percent of all cases of lung cancer reported worldwide is small cell lung cancer (SCLC). (Ihde, *Cancer* 1984, 54, 2722). Currently, treatment of SCLC incorporates multi-modal therapy, including chemotherapy, radiation therapy and surgery. Response rates of localized or disseminated SCLC remain high to systemic chemotherapy, however, persistence of the primary tumor and persistence of the tumor in the associated lymph nodes has led to the integration of several therapeutic modalities in the treatment of SCLC.

The most preferred chemotherapeutic agents against SCLC include vincristine, cisplatin, carboplatin, cyclophosphamide, epirubicin (high dose), etoposide (VP-16) I.V., etoposide (VP-16) oral, isofamide, teniposide (VM-26), and doxorubicin. Preferred single-agents chemotherapeutic agents include BCNU (carmustine), vindesine, hexamethylmelamine (altretamine), methotrexate, nitrogen mustard, and CCNU (lomustine). Other chemotherapeutic agents under investigation that have shown activity against SCLC include iroplatin, gemcitabine, lonidamine, and taxol. Single-agent chemotherapeutic agents that have not shown activity against SCLC include mitoguazone, mitomycin C, aclarubicin, diaziquone, bisantrene, cytarabine, idarubicin, mitomxantrone, vinblastine, PCNU and esorubicin.

The poor results reported from single-agent chemotherapy has led to use of combination chemotherapy.

-58-

Additionally, radiation therapy in conjunction with the preferred combinations of angiogenesis inhibitors and systemic chemotherapy is contemplated to be effective at increasing the response rate for SCLC patients. The typical dosage regimen for radiation therapy ranges from 40 to 55 Gy, in 15 to 30 fractions, 3 to 7 times week. The tissue volume to be irradiated is determined by several factors and generally the hilum and subcarinal nodes, and bialteral mdiastinal nodes up to the thoracic inlet are treated, as well as the primary tumor up to 1.5 to 2.0 cm of the margins.

Breast Cancer

Today, among women in the United States, breast cancer remains the most frequent diagnoses cancer. One in 8 women in the United States at risk of developing breast cancer in their lifetime. Age, family history, diet, and genetic factors have been identified as risk factors for breast cancer. Breast cancer is the second leading cause of death among women.

Different chemotherapeutic agents are known in the art for treating breast cancer. Cytotoxic agents used for treating breast cancer include doxorubicin, cyclophosphamide, methotrexate, 5-fluorouracil, mitomycin C, mitoxantrone, taxol, and epirubicin. (CANCER SURVEYS, Breast Cancer volume 18, Cold Spring Harbor Laboratory Press, 1993).

In the treatment of locally advanced noninflammatory breast cancer, a COX-2 inhibitor and radiation therapy can be used to treat the disease

-59-

in combination with other antiangiogenic agents, or
in combination with surgery, or with
chemotherapeutic agents. Preferred combinations of
chemotherapeutic agents, and surgery that can be
5 used in combination with the radiation therapy and
COX-2 inhibitors include, but are not limited to: 1)
doxorubicin, vincristine; 2) cyclophosphamide,
doxorubicin, 5-flourouracil, vincristine,
prednisone; 3) cyclophosphamide, doxorubicin, 5-
10 flourouracil, premarin, tamoxifen; 4)
cyclophosphamide, doxorubicin, 5-flourouracil,
premarin, tamoxifen, mastectomy; 5) mastectomy,
levamisole; 6) mastectomy; and 7) mastectomy,
cyclophosphamide, doxorubicin, 5-fluorouracil,
15 tamoxifen, halotestin.

In the treatment of locally advanced
inflammatory breast cancer, COX-2 inhibitors and
radiation therapy can be used to treat the disease
in combination with other antiangiogenic agents, or
20 in combination with surgery, or with
chemotherapeutic agents. Preferred combinations of
chemotherapeutic agents, radiation therapy and
surgery that can be used in combination with the
COX-2 inhibitors and radiation include, but or not
25 limited to: 1) cyclophosphamide, doxorubicin, 5-
fluorouracil; 2) cyclophosphamide, doxorubicin, 5-
fluorouracil, mastectomy; 3) 5-flurouracil,
doxorubicin, clyclophosphamide, vincristine,
prednisone, mastectomy; 4) 5-flurouracil,
30 doxorubicin, clyclophosphamide, vincristine,
mastectomy; 5) cyclophosphamide, doxorubicin, 5-

-60-

- fluorouracil, vincristine; 6) cyclophosphamide, doxorubicin, 5-fluorouracil, vincristine, mastectomy; 7) doxorubicin, vincristine, methotrexate, followed by vincristine,
- 5 cyclophosphamide, 5-fluorouracil; 8) doxorubicin, vincristine, cyclophosphamide, methotrexate, 5-fluorouracil, followed by vincristine, cyclophosphamide, 5-fluorouracil; 9) surgery, followed by cyclophosphamide, methotrexate, 5-
- 10 fluorouracil, prednisone, tamoxifen, followed by cyclophosphamide, methotrexate, 5-fluorouracil, prednisone, tamoxifen, doxorubicin, vincristine, tamoxifen; 10) surgery, followed by cyclophosphamide, methotrexate, 5-fluorouracil,
- 15 followed by cyclophosphamide, methotrexate, 5-fluorouracil, prednisone, tamoxifen, doxorubicin, vincristine, tamoxifen; 11) surgery, followed by cyclophosphamide, methotrexate, 5-fluorouracil, prednisone, tamoxifen, followed by cyclophosphamide,
- 20 methotrexate, 5-fluorouracil, doxorubicin, vincristine, tamoxifen;; 12) surgery, followed by cyclophosphamide, methotrexate, 5-fluorouracil, followed by cyclophosphamide, methotrexate, 5-fluorouracil, prednisone, tamoxifen, doxorubicin,
- 25 vincristine; 13) surgery, followed by cyclophosphamide, methotrexate, 5-fluorouracil, prednisone, tamoxifen, followed by cyclophosphamide, methotrexate, 5-fluorouracil, prednisone, tamoxifen, doxorubicin, vincristine, tamoxifen; 14) surgery,
- 30 followed by cyclophosphamide, methotrexate, 5-fluorouracil, followed by cyclophosphamide,

-61-

methotrexate, 5-fluorouracil, predinsone, tamoxifen,
doxorubicin, vincristine; 15) surgery, followed by
cyclophosphamide, methotrexate, 5-fluorouracil,
predinsone, tamoxifen, followed by cyclophosphamide,
5 methotrexate, 5-fluorouracil, doxorubicin,
vincristine; 16) 5-florouracil, doxorubicin,
cyclophosphamide followed by mastectomy, followed by
5-florouracil, doxorubicin, cyclophosphamide.

In the treatment of metastatic breast cancer,
10 radiation therapy and COX-2 inhibitors are used to
treat the disease in combination with surgery, or
with chemotherapeutic agents. Preferred
combinations of chemotherapeutic agents, and surgery
that can be used in combination with the radiation
15 therapy and COX-2 inhibitors include, but are not
limited to: 1) cyclophosphamide, methotrexate, 5-
fluorouracil; 2) cyclophosphamide, adriamycin, 5-
fluorouracil; 3) cyclophosphamide, methotrexate, 5-
flurouracil, vincristine, prednisone; 4) adriamycin,
20 vincristine; 5) thiotepa, adriamycin, vinblastine;
6) mitomycin, vinblastine; 7) cisplatin, etoposide.

Bladder Cancer

The classification of bladder cancer is divided
into three main classes: 1) superficial disease, 2)
25 muscle-invasive disease, and 3) metastatic disease.

Currently, transurethral resection (TUR), or
segmental resection, account for first line therapy
of superficial bladder cancer, i.e., disease
confined to the mucosa or the lamina propria.
30 However, intravesical therapies are necessary, for
example, for the treatment of high-grade tumors,

-62-

carcinoma in situ, incomplete resections, recurrences, and multifocal papillary. Recurrence rates range from up to 30 to 80 percent, depending on stage of cancer.

5 Therapies that are currently used as intravesical therapies include chemotherapy, immuonotherapy, bacille Calmette-Guerin (BCG) and photodynamic therapy. The main objective of intravesical therapy is twofold: to prevent
10 recurrence in high-risk patients and to treat disease that cannot be resected. The use of intravesical therapies must be balanced with its potentially toxic side effects. Additionally, BCG requires an unimpaired immune system to induce an
15 antitumor effect. Chemotherapeutic agents that are known to be inactive against superficial bladder cancer include Cisplatin, actinomycin D, 5-fluorouracil, bleomycin, and cyclophosphamide methotrxate.

20 In the treatment of superficial bladder cancer, COX-2 inhibitors and radiation therapy are used to treat the disease in combination with surgery (TUR), and intravesical therapies.

Preferred combinations of chemotherapeutic
25 agents are selected from the group consisting of thiotepa (30 to 60 mg/day), mitomycin C (20 to 60 mg/day), and doxorubicin (20 to 80 mg/day).

The preferred intravesicle immunotherapeutic agent that may be used in the present invention is
30 BCG. The preferred daily dose ranges from 60 to 120

-63-

mg, depending on the strain of the live attenuated tuberculosis organism used.

The preferred photodynamic therapeutic agent that may be used with the present invention is

5 Photofrin I, a photosensitizing agent, administered intravenously. It is taken up by the low-density lipoprotein receptors of the tumor cells and is activated by exposure to visible light.

Additionally, neomydium YAG laser activation

10 generates large amounts of cytotoxic free radicals and singlet oxygen.

In the treatment of muscle-invasive bladder cancer, radiation therapy and COX-2 inhibitors can be used to treat the disease in combination with

15 other antiangiogenic agents, or in combination with surgery (TUR), intravesical chemotherapy, and radical cystectomy with pelvic lymph node dissection.

The preferred radiation dose is between 5,000

20 to 7,000 cGY in fractions of 180 to 200 cGY to the tumor. Additionally, 3,500 to 4,700 cGY total dose is administered to the normal bladder and pelvic contents in a four-field technique. Radiation therapy should be considered only if the patient is

25 not a surgical candidate, but may be considered as preoperative therapy.

The preferred combination of chemotherapeutic agents that can be used in combination with radiation therapy and the COX-2 inhibitors is

30 cisplatin, methotrexate, vinblastine.

-64-

Currently no curative therapy exists for metastatic bladder cancer. The present invention contemplates an effective treatment of bladder cancer leading to improved tumor inhibition or regression, as compared to current therapies.

In the treatment of metastatic bladder cancer, a combination of radiation therapy and COX-2 inhibitors can be used to treat the disease in combination with surgery, or with chemotherapeutic agents.

Preferred combinations of chemotherapeutic agents include, but are not limited to: 1) cisplatin and methotrexate; 2) doxorubicin, vinblastine, cyclophosphamide, and 5-fluorouracil; 3) vinblastine, doxorubicin, cisplatin, methotrexate; 4) vinblastine, cisplatin, methotrexate; 5) cyclophosphamide, doxorubicin, cisplatin; 6) 5-fluorouracil, cisplatin.

Head and Neck Cancers

Head and neck cancer accounts for approximately 2% of new cancer cases in the United States. Common intracranial neoplasms include glioma, meningioma, neurinoma, and adenoma.

Preferred combinations that can be used along with a combination of radiation therapy and a COX-2 inhibitor for the treatment of malignant glioma include: 1) BCNU (carmustine); 2) methyl CCNU (lomustine); 3) medrol; 4) procarbazine; 5) BCNU, medrol; 6) misonidazole, BCNU; 7) streptozotocin; 8) BCNU, procarbazine; 9) BCNU, hydroxyurea, procarbazine, VM-26; 10) BNCU, 5-fluorouracil; 11)

-65-

methy1 CCNU, dacarbazine; 12) misonidazole, BCNU;
and 13) PCNU. The preferred dose of radiation
therapy is about 5,500 to about 6,000 cGY.
Preferred radiosensitizers include misonidazole,
5 intra-arterial Budr and intravenous iododeoxyuridine
(IUDR).

Biological Evaluation

10 NFSA tumor

The NFSA sarcoma is a nonimmunogenic and
prostaglandin producing tumor that spontaneously
developed in C3Hf/Kam mice. It exhibits an increased
radioresponse if indomethacin is given prior to
15 tumor irradiation. The NFSA tumor is relatively
radioresistant and is strongly infiltrated by
inflammatory mononuclear cells, primarily
macrophages which secrete factors that stimulate
tumor cell proliferation. Furthermore, this tumor
20 produces a number of prostaglandins, including
prostaglandin E₂ and prostaglandin I₂.

Solitary tumors were generated in the right
hind legs of mice by the injection of 3×10^5 viable
NFSA tumor cells. Treatment with a COX-2 inhibitor
25 (6 mg/kg body weight) or vehicle (0.05% Tween 20 and
0.95% polyethylene glycol) given in the drinking
water was started when tumors were approximately 6
mm in diameter and the treatment was continued for
10 consecutive days. Water bottles were changed
30 every 3 days. In some experiments, tumor
irradiation was performed 3-8 days after initiation

-66-

of the treatment with a COX-2 inhibitor. The end points of the treatment were tumor growth delay (days) and TCD₅₀ (tumor control dose 50, defined as the radiation dose yielding local tumor cure in 50% of irradiated mice 120 days after irradiation). To obtain tumor growth curves, three mutually orthogonal diameters of tumors were measured daily with a vernier caliper, and the mean values were calculated. In Fig. 1, which plots the growth of tumor treated with vehicle (o) or COX-2 inhibitor (•), the groups consisted of eight mice each, respectively. Treatment of mice with a COX-2 inhibitor alone significantly inhibited tumor growth.

Local tumor irradiation with single γ -ray doses of 30, 40, or 50 Gy was given when these tumors reached 8 mm in diameter. Irradiation to the tumor was delivered from a dual-source ¹³⁷Cs irradiator at a dose rate of 6.31 Gy/minute. During irradiation, unanesthetized mice were immobilized on a jig and the tumor was centered in a circular radiation field 3 cm in diameter. Regression and regrowth of tumors were followed at 1-3 day intervals until the tumor diameter reached approximately 14 mm. Fig. 2 plots the growth curves to illustrate the effect of a COX-2 inhibitor on tumor growth when combined with a radiation dose of 30 Gy. Day 0 designates the time of tumor irradiation; it should be noted, however, that tumors in the groups receiving a COX-2 inhibitor reached the size of 8 mm (day 0) at a later time than tumors treated with the vehicle.

-67-

Groups consisted of five to eight mice each. Two of eight mice in the COX-2 inhibitor only group died of unknown causes. (O = vehicle, Δ = COX-2 inhibitor, \bullet = 30 Gy, and \blacktriangle = COX-2 inhibitor plus 30 Gy).

5 Vertical bars represent 95% confidence intervals.

Tumor diameter doubling time, based on tumor growth from 6 to 12 mm in diameter, was increased from 7.3 days (95% confidence interval [CI] = 6.48.1 days) to 14.8 days (95% CI = 11.5-18.1 days)

10 (P<.0001). The effect of a COX-2 inhibitor was evident already within 1 day from the start of the treatment.

The magnitude of tumor growth delay as a function of radiation dose with or without treatment with a COX-2 inhibitor was plotted (Fig. 3) to
15 determine the enhancement of tumor response to radiation. This requires that tumor growth delay after radiation be expressed only as the absolute tumor growth delay, i.e., the time in days for
20 tumors treated with radiation to grow from 8 to 12 mm in diameter minus the time in days for untreated tumors to reach the same size. It also requires that the effect of the combined a COX-2 inhibitor plus-radiation treatment be expressed as the normalized
25 tumor growth delay. Normalized tumor growth delay is defined as the time for tumors treated with both a COX-2 inhibitor and radiation to grow from 8 to 12 mm in diameter minus the time in days for tumors treated with a COX-2 inhibitor alone to reach the
30 same size. Absolute tumor growth delay and normalized tumor growth delay along with their 95%

-68-

confidence intervals were plotted for all three radiation doses used in this experiment (30, 40, and 50 Gy). The enhancement factor was 3.64 (95% confidence interval = 3.42-3.86), obtained by use of a likelihood analysis, to fit the ratio of the slopes of the two lines. While no tumors were cured by any of the three radiation doses given alone, tumors in one of six, in two of six, and in one of eight animals were cured when a COX-2 inhibitor treatment was combined with radiation treatment at 30, 40, and 50 Gy, respectively. Two of eight mice in the group that received the COX-2 inhibitor plus 40 Gy died of unknown causes. The mice whose tumors were cured and the mice that died were not included in tumor growth delay analysis.

The entire procedure for treatment with a COX-2 inhibitor and local tumor irradiation was the same as that described in Figs. 2-3. Here, the single doses of γ -radiation ranged from 25 to 80 Gy. Mice were checked for the presence of tumor at the irradiated site at 2- to 7-day intervals for up to 120 days, at which time TCD_{50} values were calculated. TCD_{50} values (tumor control dose 50 designates a radiation dose yielding 50% control [regression] of local tumor) were computed by use of the logistic model (Finney, Quartel response and the tolerance distribution. Statistical methods in biological Assay, 2nd Ed., 1952) and shown in Fig. 4 (● - radiation only and ▲ - COX-2 inhibitor plus radiation. Horizontal bars represent 95% confidence intervals, at the TCD_{50} dose level. Five of 60 mice

-69-

that received a COX-2 inhibitor plus radiation died of unknown causes. The dead mice were excluded from TCD₅₀ analysis. TCD₅₀ assays contained 57 mice that received radiation only and 55 mice that received a combination of the COX-2 inhibitor and radiation.

A COX-2 inhibitor co-treatment increased the effect of tumor irradiation, as shown by both tumor growth delay (Fig. 2 and 3) and tumor cure rate (Fig. 4). The growth delay after the combined treatment was more than the sum of growth delays caused by either irradiation alone or a COX-2 inhibitor alone (Fig. 2). Tumors in control mice required 4.6 days (95% CI = 3.9-5.4 days) to grow from 8 to 12 mm in diameter. Mice treated with a COX-2 inhibitor required 7.1 days (95% CI = 5.0-9.2 days) (P = .003), mice treated with 30 Gy required 13.6 days (95% CI = 10.5-16.7 days), and mice treated with both agents required 43.5 days (95% CI = 30.8-56.2 days) (P = .001 compared with radiation-only group). The efficacy of irradiation was enhanced by a factor of 3.64 (95% CI = 3.42-3.86), determined from the curves in Fig. 3, which plot the magnitude of tumor growth delay as a function of radiation dose with or without treatment with a COX-2 inhibitor. This compound also greatly enhanced the tumor cure rate after irradiation (Fig. 4). The TCD₅₀ value was reduced from 69.2 Gy (95% CI = 65.7-72.7 Gy) in the irradiation-only group to 39.2 Gy (95% CI = 31.1- 44.6 Gy) in the combination-treatment group. The enhancement factor was 1.77 (95% CI = 1.5 1-1,99). obtained by dividing the TCD₅₀ value of the

-70-

radiation-alone group by the combination-treatment group. The 95% CI's were obtained by use of Fieller's theorem (Heron, J. Statist. Comput. Simul., 1975, 3, 265-74).

5 A COX-2 inhibitor dramatically enhanced the tumor response to radiation, as evidenced by the increase in tumor growth delay and the augmentation of tumor curability. The enhancement factors were 3.64 and 1.77, respectively, greater than the
10 enhancement factors of 1.4 and 1.26 for radiation-indomethacin and radiation alone, respectively.

 All documents referenced herein are incorporated by reference.

 Although this invention has been described with
15 respect to specific embodiments, the details of these embodiments are not to be construed as limitations.

20

-71-


What is claimed is:

1. A method for treating neoplasia in a subject in need of such treatment, the method comprises treating the subject with radiation therapy and a therapeutically effective amount of a cyclooxygenase-2 inhibitor or pharmaceutically-acceptable salt or derivative thereof.


2. The method of Claim 1 wherein the neoplasia is selected from lung cancer, breast cancer, gastrointestinal cancer, bladder cancer, head and neck cancer and cervical cancer.

3. A method for treating neoplasia in a subject in need of such treatment, the method comprises treating the subject with radiation therapy and a therapeutically effective amount of a cyclooxygenase-2 inhibitor or pharmaceutically-acceptable salt or derivative thereof, wherein the cyclooxygenase-2 inhibitor is selected from compounds, and their pharmaceutically acceptable salts, of the group consisting of

1)




2)




-72-


3)




4)




5)




6)



7)




8)




10

9)




10)




-73-


11)



12)




13)




5


14)



15)




16)




-74-


17)




18)



19)




20)




5

21)




22)




10

23)




24)




-75-


25)




26)



27)




28)




5

29)




30)




-76-


31)



32)




33)




5


34)



35)




36)




-77-


37)




38)



39)




40)




5

41)




42)




10

43)



44)



and

4. A method for treating neoplasia in a subject in need of such treatment, the method comprises

-78-

- treating the subject with radiation therapy and a therapeutically effective amount of a cyclooxygenase-2 inhibitor or pharmaceutically-acceptable or derivative thereof, wherein the
- 5 cyclooxygenase-2 inhibitor is selected from compounds, and their pharmaceutically acceptable salts, of the group consisting of
- 5-(4-fluorophenyl)-1-[4-(methylsulfonyl)phenyl]-3-(trifluoromethyl)pyrazole;
- 10 4-(4-fluorophenyl)-5-[4-(methylsulfonyl)phenyl]-1-phenyl-3-(trifluoromethyl)pyrazole;
- 4-(5-(4-chlorophenyl)-3-(4-methoxyphenyl)-1H-pyrazol-1-yl)benzenesulfonamide
- 4-(3,5-bis(4-methylphenyl)-1H-pyrazol-1-yl)benzenesulfonamide;
- 15 4-(5-(4-chlorophenyl)-3-phenyl-1H-pyrazol-1-yl)benzenesulfonamide;
- 4-(3,5-bis(4-methoxyphenyl)-1H-pyrazol-1-yl)benzenesulfonamide;
- 20 4-(5-(4-chlorophenyl)-3-(4-methylphenyl)-1H-pyrazol-1-yl)benzenesulfonamide;
- 4-(5-(4-chlorophenyl)-3-(4-nitrophenyl)-1H-pyrazol-1-yl)benzenesulfonamide;
- 4-(5-(4-chlorophenyl)-3-(5-chloro-2-thienyl)-1H-pyrazol-1-yl)benzenesulfonamide;
- 25 4-(4-chloro-3,5-diphenyl-1H-pyrazol-1-yl)benzenesulfonamide
- 4-[5-(4-chlorophenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl]benzenesulfonamide;
- 30 4-[5-phenyl-3-(trifluoromethyl)-1H-pyrazol-1-yl]benzenesulfonamide;

- 4-[5-(4-fluorophenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl]benzenesulfonamide;
- 4-[5-(4-methoxyphenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl]benzenesulfonamide;
- 5 4-[5-(4-chlorophenyl)-3-(difluoromethyl)-1H-pyrazol-1-yl]benzenesulfonamide;
- 4-[5-(4-methylphenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl]benzenesulfonamide;
- 4-[4-chloro-5-(4-chlorophenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl]benzenesulfonamide;
- 10 4-[3-(difluoromethyl)-5-(4-methylphenyl)-1H-pyrazol-1-yl]benzenesulfonamide;
- 4-[3-(difluoromethyl)-5-phenyl-1H-pyrazol-1-yl]benzenesulfonamide;
- 15 4-[3-(difluoromethyl)-5-(4-methoxyphenyl)-1H-pyrazol-1-yl]benzenesulfonamide;
- 4-[3-cyano-5-(4-fluorophenyl)-1H-pyrazol-1-yl]benzenesulfonamide;
- 4-[3-(difluoromethyl)-5-(3-fluoro-4-methoxyphenyl)-1H-pyrazol-1-yl]benzenesulfonamide;
- 20 4-[5-(3-fluoro-4-methoxyphenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl]benzenesulfonamide;
- 4-[4-chloro-5-phenyl-1H-pyrazol-1-yl]benzenesulfonamide;
- 25 4-[5-(4-chlorophenyl)-3-(hydroxymethyl)-1H-pyrazol-1-yl]benzenesulfonamide;
- 4-[5-(4-(N,N-dimethylamino)phenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl]benzenesulfonamide;
- 30 5-(4-fluorophenyl)-6-[4-(methylsulfonyl)phenyl]spiro[2.4]hept-5-ene;

-80-

- 4-[6-(4-fluorophenyl)spiro[2.4]hept-5-en-5-yl]benzenesulfonamide;
6-(4-fluorophenyl)-7-[4-(methylsulfonyl)phenyl]spiro[3.4]oct-6-ene;
- 5 5-(3-chloro-4-methoxyphenyl)-6-[4-(methylsulfonyl)phenyl]spiro[2.4]hept-5-ene;
4-[6-(3-chloro-4-methoxyphenyl)spiro[2.4]hept-5-en-5-yl]benzenesulfonamide;
- 10 5-(3,5-dichloro-4-methoxyphenyl)-6-[4-(methylsulfonyl)phenyl]spiro[2.4]hept-5-ene;
5-(3-chloro-4-fluorophenyl)-6-[4-(methylsulfonyl)phenyl]spiro[2.4]hept-5-ene;
4-[6-(3,4-dichlorophenyl)spiro[2.4]hept-5-en-5-yl]benzenesulfonamide;
- 15 2-(3-chloro-4-fluorophenyl)-4-(4-fluorophenyl)-5-(4-methylsulfonylphenyl)thiazole;
2-(2-chlorophenyl)-4-(4-fluorophenyl)-5-(4-methylsulfonylphenyl)thiazole;
5-(4-fluorophenyl)-4-(4-methylsulfonylphenyl)-2-
- 20 methylthiazole;
4-(4-fluorophenyl)-5-(4-methylsulfonylphenyl)-2-trifluoromethylthiazole;
4-(4-fluorophenyl)-5-(4-methylsulfonylphenyl)-2-(2-thienyl)thiazole;
- 25 4-(4-fluorophenyl)-5-(4-methylsulfonylphenyl)-2-benzylaminothiazole;
4-(4-fluorophenyl)-5-(4-methylsulfonylphenyl)-2-(1-propylamino)thiazole;
2-[(3,5-dichlorophenoxy)methyl]-4-(4-fluorophenyl)-
- 30 5-[4-(methylsulfonyl)phenyl]thiazole;

-81-

- 5-(4-fluorophenyl)-4-(4-methylsulfonylphenyl)-2-trifluoromethylthiazole;
- 1-methylsulfonyl-4-[1,1-dimethyl-4-(4-fluorophenyl)cyclopenta-2,4-dien-3-yl]benzene;
- 5 4-[4-(4-fluorophenyl)-1,1-dimethylcyclopenta-2,4-dien-3-yl]benzenesulfonamide;
- 5-(4-fluorophenyl)-6-[4-(methylsulfonyl)phenyl]spiro[2.4]hepta-4,6-diene;
- 4-[6-(4-fluorophenyl)spiro[2.4]hepta-4,6-dien-5-yl]benzenesulfonamide;
- 10 6-(4-fluorophenyl)-2-methoxy-5-[4-(methylsulfonyl)phenyl]-pyridine-3-carbonitrile;
- 2-bromo-6-(4-fluorophenyl)-5-[4-(methylsulfonyl)phenyl]-pyridine-3-carbonitrile;
- 15 6-(4-fluorophenyl)-5-[4-(methylsulfonyl)phenyl]-2-phenylpyridine-3-carbonitrile;
- 4-[2-(4-methylpyridin-2-yl)-4-(trifluoromethyl)-1H-imidazol-1-yl]benzenesulfonamide;
- 4-[2-(5-methylpyridin-3-yl)-4-(trifluoromethyl)-1H-imidazol-1-yl]benzenesulfonamide;
- 20 4-[2-(2-methylpyridin-3-yl)-4-(trifluoromethyl)-1H-imidazol-1-yl]benzenesulfonamide;
- 3-[1-[4-(methylsulfonyl)phenyl]-4-(trifluoromethyl)-1H-imidazol-2-yl]pyridine;
- 25 2-[1-[4-(methylsulfonyl)phenyl]-4-(trifluoromethyl)-1H-imidazol-2-yl]pyridine;
- 2-methyl-4-[1-[4-(methylsulfonyl)phenyl]-4-(trifluoromethyl)-1H-imidazol-2-yl]pyridine;
- 2-methyl-6-[1-[4-(methylsulfonyl)phenyl]-4-(trifluoromethyl)-1H-imidazol-2-yl]pyridine;
- 30

-82-

- 4-[2-(6-methylpyridin-3-yl)-4-(trifluoromethyl)-1H-imidazol-1-yl]benzenesulfonamide;
2-(3,4-difluorophenyl)-1-[4-(methylsulfonyl)phenyl]-4-(trifluoromethyl)-1H-imidazole;
- 5 4-[2-(4-methylphenyl)-4-(trifluoromethyl)-1H-imidazol-1-yl]benzenesulfonamide;
2-(4-chlorophenyl)-1-[4-(methylsulfonyl)phenyl]-4-methyl-1H-imidazole;
2-(4-chlorophenyl)-1-[4-(methylsulfonyl)phenyl]-4-phenyl-1H-imidazole;
- 10 2-(4-chlorophenyl)-4-(4-fluorophenyl)-1-[4-(methylsulfonyl)phenyl]-1H-imidazole;
2-(3-fluoro-4-methoxyphenyl)-1-[4-(methylsulfonyl)phenyl]-4-(trifluoromethyl)-1H-imidazole;
- 15 1-[4-(methylsulfonyl)phenyl]-2-phenyl-4-trifluoromethyl-1H-imidazole;
2-(4-methylphenyl)-1-[4-(methylsulfonyl)phenyl]-4-trifluoromethyl-1H-imidazole;
- 20 4-[2-(3-chloro-4-methylphenyl)-4-(trifluoromethyl)-1H-imidazol-1-yl]benzenesulfonamide;
2-(3-fluoro-5-methylphenyl)-1-[4-(methylsulfonyl)phenyl]-4-(trifluoromethyl)-1H-imidazole;
- 25 4-[2-(3-fluoro-5-methylphenyl)-4-(trifluoromethyl)-1H-imidazol-1-yl]benzenesulfonamide;
2-(3-methylphenyl)-1-[4-(methylsulfonyl)phenyl]-4-trifluoromethyl-1H-imidazole;
- 30 4-[2-(3-methylphenyl)-4-trifluoromethyl-1H-imidazol-1-yl]benzenesulfonamide;

-83-

- 1-[4-(methylsulfonyl)phenyl]-2-(3-chlorophenyl)-4-trifluoromethyl-1H-imidazole;
- 4-[2-(3-chlorophenyl)-4-trifluoromethyl-1H-imidazol-1-yl]benzenesulfonamide;
- 5 4-[2-phenyl-4-trifluoromethyl-1H-imidazol-1-yl]benzenesulfonamide;
- 4-[2-(4-methoxy-3-chlorophenyl)-4-trifluoromethyl-1H-imidazol-1-yl]benzenesulfonamide;
- 1-allyl-4-(4-fluorophenyl)-3-[4-(methylsulfonyl)phenyl]-5-(trifluoromethyl)-1H-pyrazole;
- 10 4-[1-ethyl-4-(4-fluorophenyl)-5-(trifluoromethyl)-1H-pyrazol-3-yl]benzenesulfonamide;
- N-phenyl-[4-(4-fluorophenyl)-3-[4-(methylsulfonyl)phenyl]-5-(trifluoromethyl)-1H-pyrazol-1-yl]acetamide;
- 15 ethyl [4-(4-fluorophenyl)-3-[4-(methylsulfonyl)phenyl]-5-(trifluoromethyl)-1H-pyrazol-1-yl]acetate;
- 20 4-(4-fluorophenyl)-3-[4-(methylsulfonyl)phenyl]-1-(2-phenylethyl)-1H-pyrazole;
- 4-(4-fluorophenyl)-3-[4-(methylsulfonyl)phenyl]-1-(2-phenylethyl)-5-(trifluoromethyl)pyrazole;
- 1-ethyl-4-(4-fluorophenyl)-3-[4-(methylsulfonyl)phenyl]-5-(trifluoromethyl)-1H-pyrazole;
- 25 5-(4-fluorophenyl)-4-(4-methylsulfonylphenyl)-2-trifluoromethyl-1H-imidazole;
- 4-[4-(methylsulfonyl)phenyl]-5-(2-thiophenyl)-2-(trifluoromethyl)-1H-imidazole;
- 30

-84-

- 5-(4-fluorophenyl)-2-methoxy-4-[4-(methylsulfonyl)phenyl]-6-(trifluoromethyl)pyridine;
- 2-ethoxy-5-(4-fluorophenyl)-4-[4-(methylsulfonyl)phenyl]-6-(trifluoromethyl)pyridine;
- 5 5-(4-fluorophenyl)-4-[4-(methylsulfonyl)phenyl]-2-(2-propynyloxy)-6-(trifluoromethyl)pyridine;
- 2-bromo-5-(4-fluorophenyl)-4-[4-(methylsulfonyl)phenyl]-6-(trifluoromethyl)pyridine;
- 10 4-[2-(3-chloro-4-methoxyphenyl)-4,5-difluorophenyl]benzenesulfonamide;
- 1-(4-fluorophenyl)-2-[4-(methylsulfonyl)phenyl]benzene;
- 15 5-difluoromethyl-4-(4-methylsulfonylphenyl)-3-phenylisoxazole;
- 4-[3-ethyl-5-phenylisoxazol-4-yl]benzenesulfonamide;
- 4-[5-difluoromethyl-3-phenylisoxazol-4-yl]benzenesulfonamide;
- 20 4-[5-hydroxymethyl-3-phenylisoxazol-4-yl]benzenesulfonamide;
- 4-[5-methyl-3-phenyl-isoxazol-4-yl]benzenesulfonamide;
- 25 1-[2-(4-fluorophenyl)cyclopenten-1-yl]-4-(methylsulfonyl)benzene;
- 1-[2-(4-fluoro-2-methylphenyl)cyclopenten-1-yl]-4-(methylsulfonyl)benzene;
- 1-[2-(4-chlorophenyl)cyclopenten-1-yl]-4-(methylsulfonyl)benzene;
- 30

- 1-[2-(2,4-dichlorophenyl)cyclopenten-1-yl]-4-(methylsulfonyl)benzene;
- 1-[2-(4-trifluoromethylphenyl)cyclopenten-1-yl]-4-(methylsulfonyl)benzene;
- 5 1-[2-(4-methylthiophenyl)cyclopenten-1-yl]-4-(methylsulfonyl)benzene;
- 1-[2-(4-fluorophenyl)-4,4-dimethylcyclopenten-1-yl]-4-(methylsulfonyl)benzene;
- 4-[2-(4-fluorophenyl)-4,4-dimethylcyclopenten-1-yl]benzenesulfonamide;
- 10 1-[2-(4-chlorophenyl)-4,4-dimethylcyclopenten-1-yl]-4-(methylsulfonyl)benzene;
- 4-[2-(4-chlorophenyl)-4,4-dimethylcyclopenten-1-yl]benzenesulfonamide;
- 15 4-[2-(4-fluorophenyl)cyclopenten-1-yl]benzenesulfonamide;
- 4-[2-(4-chlorophenyl)cyclopenten-1-yl]benzenesulfonamide;
- 1-[2-(4-methoxyphenyl)cyclopenten-1-yl]-4-(methylsulfonyl)benzene;
- 20 1-[2-(2,3-difluorophenyl)cyclopenten-1-yl]-4-(methylsulfonyl)benzene;
- 4-[2-(3-fluoro-4-methoxyphenyl)cyclopenten-1-yl]benzenesulfonamide;
- 25 1-[2-(3-chloro-4-methoxyphenyl)cyclopenten-1-yl]-4-(methylsulfonyl)benzene;
- 4-[2-(3-chloro-4-fluorophenyl)cyclopenten-1-yl]benzenesulfonamide;
- 4-[2-(2-methylpyridin-5-yl)cyclopenten-1-yl]benzenesulfonamide;
- 30


-86-

ethyl 2-[4-(4-fluorophenyl)-5-[4-(methylsulfonyl)
phenyl]oxazol-2-yl]-2-benzyl-acetate;
2-[4-(4-fluorophenyl)-5-[4-
(methylsulfonyl)phenyl]oxazol-2-yl]acetic acid;
5 2-(*tert*-butyl)-4-(4-fluorophenyl)-5-[4-
(methylsulfonyl)phenyl]oxazole;
4-(4-fluorophenyl)-5-[4-(methylsulfonyl)phenyl]-2-
phenyloxazole;
4-(4-fluorophenyl)-2-methyl-5-[4-
10 (methylsulfonyl)phenyl]oxazole; and
4-[5-(3-fluoro-4-methoxyphenyl)-2-trifluoromethyl-4-
oxazolyl]benzenesulfonamide.

5. The method of Claim 4 wherein the
15 cyclooxygenase-2 inhibitor is 4-[5-(4-methylphenyl)-
3-(trifluoromethyl)-1H-pyrazol-1-
yl]benzenesulfonamide.

6. A combination comprising radiation therapy
20 and a therapeutically effective amount of a
cyclooxygenase-2 inhibitor or pharmaceutically-
acceptable salt or derivative thereof.

1/4

*Fig. 1*

2/4





Fig. 2

3/4

*Fig. 3*

4/4




Fig. 4

INTERNATIONAL SEARCH REPORT

International Application No.

PCT/US 99/30669

A. CLASSIFICATION OF SUBJECT MATTER

IPC 7 A61K41/00 A61P35/00

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 7 A61K A61P

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	WO 98 16227 A (GORDON GARY B ;SEARLE & CO (US); SEIBERT KAREN (US); MASFERRER JAI) 23 April 1998 (1998-04-23) cited in the application page 3, line 1-8 page 24, line 7 -page 29, line 6 claim 2	1-6
P, X	EP 0 927 555 A (SANKYO CO) 7 July 1999 (1999-07-07) claim 42 page 24, line 28-34 --- -/--	1-6

☒ Further documents are listed in the continuation of box C.

☒ Patent family members are listed in annex.

* Special categories of cited documents:

- *A* document defining the general state of the art which is not considered to be of particular relevance
- *E* earlier document but published on or after the international filing date
- *L* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- *O* document referring to an oral disclosure, use, exhibition or other means
- *P* document published prior to the international filing date but later than the priority date claimed

- *T* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
- *X* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
- *Y* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.
- *G* document member of the same patent family

Date of the actual completion of the international search

6 April 2000

Date of mailing of the international search report

27. 04. 00

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,
Fax: (+31-70) 340-3016

Authorized officer

Herrera, S

INTERNATIONAL SEARCH REPORT

Int .tional Application No
PCT/US 99/30669

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT		
Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
P, X	<p>BIOLOGICAL ABSTRACTS, vol. 1999, Philadelphia, PA, US; abstract no. 465128, MILAS, LUKA (1) ET AL: "Enhancement of tumor response to gamma-radiation by an inhibitor of cyclooxygenase -2 enzyme." XP002134995 abstract & JOURNAL OF THE NATIONAL CANCER INSTITUTE (BETHESDA), (SEPT. 1, 1999) VOL. 91, NO. 17, PP. 1501-1504. , _____</p>	1-6

INTERNATIONAL SEARCH REPORT

International application No.
PCT/US 99/30669

Box I Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)

This International Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☐ Claims Nos.:
because they relate to subject matter not required to be searched by this Authority, namely:
2. ☒ Claims Nos.:
because they relate to parts of the International Application that do not comply with the prescribed requirements to such an extent that no meaningful International Search can be carried out, specifically:
see FURTHER INFORMATION sheet PCT/ISA/210
3. ☐ Claims Nos.:
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

1. ☐ As all required additional search fees were timely paid by the applicant, this International Search Report covers all searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this International Search Report covers only those claims for which fees were paid, specifically claims Nos.:
4. ☐ No required additional search fees were timely paid by the applicant. Consequently, this International Search Report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest

- ☐ The additional search fees were accompanied by the applicant's protest.
- ☐ No protest accompanied the payment of additional search fees.

INTERNATIONAL SEARCH REPORT

information on patent family members

International Application No

PCT/US 99/30669

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
WO 9816227 A	23-04-1998	AU 4904897 A	11-05-1998
		BR 9712314 A	31-08-1999
		CZ 9901171 A	14-07-1999
		EP 0932402 A	04-08-1999
		NO 991793 A	15-04-1999
EP 0927555 A	07-07-1999	AU 9822598 A	15-07-1999
		CN 1230407 A	06-10-1999
		CZ 9804258 A	14-07-1999
		HU 9803018 A	28-10-1999
		JP 11246403 A	14-09-1999
		NO 986089 A	25-06-1999
		PL 330496 A	05-07-1999
		JP 11279078 A	12-10-1999